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Defining' the' role' of' microRNAE122' in' the' early' detection' of'
chemotherapyEinduced' hepatotoxicity' in' the' neoEadjuvant'
treatment'of'advanced'colorectal'cancer.'
'
Derek'McWhirter'!Colorectal! cancer! remains! one! of! the!most! common! cancers! in! the!United!Kingdom!with!around!40,000!new!cases!being!diagnosed!each!year.!Around!25%!of!patients!will!have!liver!metastases!at!the!time!of!presentation,!with!up! to! 50%!developing!metastases! at! some! point! in! their! life.! Advances! in!surgical! technique! and!developments! in! chemotherapy!have! increased! the!number! of! patients! with! advanced! disease! for! whom! potentially! curative!treatment! is! possible.! The! use! of! chemotherapy! in! a! neo2adjuvant! setting!has! improved! the! outcome! for! patients! with! liver! metastases! who! have!initially! irresectable! or! borderline! disease.! Chemotherapy2induced!hepatotoxicity! affects! up! to! 78%! of! patients! receiving! standard!chemotherapy!for!colorectal!cancer!and!can!lead!to!increased!morbidity!and!mortality.!Current!gold!standard!serum2based!biomarkers!of!drug2induced!hepatotoxicity! have! their! limitations! and! there! remains! a! need! for! more!sensitive!and!specific!novel!biomarkers!to!detect!early!hepatotoxicity.!!The!use!of!serum2based!microRNAs,!in!particular!microRNA2122!(miR2122),!a!hepatocyte2specific!molecule!has!been!proposed!as!a!possible!biomarker!for!chemotherapy2induced!hepatotoxicity.!!The!work!described!in!this!thesis!assessed!the!characteristics!of!serum!miR2122!in!a!healthy!human!population.!It!also!assessed!serum!levels!of!miR2122!in!different!diseases! including!primary! liver! cancer.! In!order! to! assess! the!role! of! serum! miR2122! in! chemotherapy2induced! hepatotoxicity,! a! pilot!study! was! carried! out! in! patients! receiving! chemotherapy! for! advanced!colorectal!cancer.!!In! a! healthy! human! population! (n=129)! serum! levels! of! miR2122! were!measured! to! investigate! the! degree! of! variation! and! define! a! normal!reference!range!that!could!be!used!to!assess!changes!found!in!patients!with!hepatic! injury! and! disease.! In! addition! to! miR2122,! two! endogenous!(U6snRNA/let27d)! and! one! exogenous! controls! (c.lin24)! were! measured.!Inter2individual!variation!was! low!for!miR2122!(CV%!5.21)!and!also!for!all!three!controls!(CV%!<4%).!There!was!no!circadian!variation!in!serum!miR2122! (ANOVA! p=0.1254).! Analysis! of! intra2patient! variation! over! three!consecutive!days!was!similarly!low!(p=0.66).!!In! a! human! population! with! underlying! chronic! liver! disease! (n=90)! and!primary!liver!cancer!(n=104),!serum!miR2122!was!significantly!raised!in!the!both! cohorts! (p=<0.001)! but! no! difference!was! seen! between! the! chronic!disease! and! cancer! cohorts! (p=0.338).! Patients! with! an! underlying!inflammatory!condition!had!significantly!raised!serum!miR2122!(p=<0.001)!
! v!
compared! to! those!with! underlying! cirrhotic! or! fibrotic! change! (p=0.372).!ROC!analysis!supported!this!finding!(AUC!0.79!vs!0.54).!!In! a! pilot! study! of! serum!miR2122! during! neo2adjuvant! chemotherapy! for!colorectal!cancer! liver!metastases,!11!patients!were!recruited.!Serial!blood!sampling!during!chemotherapy!treatment!revealed!a!non2significant!rise!in!miR2122!(p=0.14).!Clinically!insignificant!levels!of!liver!toxicity!were!seen!in!the! ten! patients! who! completed! the! treatment! and! had! surgery.! In! those!with! histology! changes! known! to! be! associated!with! chemotherapy,! there!was!a!significant!rise! in!serum!ALT!(p=0.0082!and!0.0085)!while! the!miR2122!did!not!rise!significantly!(p=0.053).!!This! work! confirmed! the! low! variation! in! serum! miR2122! that! is! a!requirement! for! a! novel! biomarker.! Furthermore,! it! confirmed! the!detectable! increase! of! serum! miR2122! in! patients! with! liver! disease,!particularly! those! with! an! inflammatory! pathophysiology.! Finally,! in! a!human!model!of!chemotherapy2related!hepatotoxicity,! the!role!of!miR2122!remains!unclear!at!present,!but!the!non2significant!changes!in!level!related!to! clinically! insignificant! liver! perturbation! compared! to! the! significant!changes! in!ALT! suggest! that,! although!more!work! is! required,! it!may!be! a!valuable!biomarker!with!potential!in!this!field.!
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1.1! Epidemiology!of!Colorectal!Cancer!!Colorectal! cancer! is! the! 3rd! most! common! cancer! in! the! United! Kingdom!accounting!for!13%!of!new!cases.!It!is!the!3rd!most!common!cancer!in!men!in!the!United!Kingdom!accounting!for!14%!of!new!cancers!and!is!the!2nd!most!common!cancer!in!females!accounting!for!12%!of!new!cases.!In!2009,!there!were! 41,142! new! cases! in! the! UK! with! a! male! to! female! ratio! of! 1.2:1.!(Cancer!Research!UK!Statistics!2009)!!It! is! the!2nd!most!common!cause!of!cancer!death!accounting! for!10%!of!all!cancer!death.! In!2010! there!were!16,013!deaths! in! the!UK! from!colorectal!cancer.!The!5Jyear!survival!varies!with!stage.!!
!Table!1:!Survival!by!Dukes!Stage.!Adapted!from!Cancer!Research!UK!Statistics!Website.!!
1.2! Genetics!of!Colorectal!Cancer!!The!majority!(70J85%)!of!colorectal!cancers!are!sporadic!tumours!with!no!obvious!hereditary!basis!to!them.!The!remaining!15J30%!of!cases!may!have!a!major! hereditary! component! to! them! such! as! Hereditary! NonJPolyposis!Colorectal!Cancer!(HNPCC)!or!Familial!Adenomatous!Polyposis!(FAP)!(1J2).!Although! they! account! for! only! a! small! percentage! of! the! total! number! of!cases! of! colorectal! cancer,! the! hereditary! tumours! have! given!us! the!most!insight! into! the! molecular! pathways! associated! with! the! development! of!these!tumours.!
Duke’s'Stage'at'Diagnosis '50year'survival'
!!!!!A ! ! !!!!!!!!93.2%!
!!!!!B ! ! !!!!!!!!77.0%!
!!!!!C ! ! !!!!!!!!!47.7%!













1.2.2!! APC!Gene!Mutation!!The! adenomatous! polyposis! coli! (APC)! gene! is! a! tumour! suppressor! gene!that!is!commonly!mutated!in!colorectal!cancer.!It!encodes!a!protein!thought!to! have! important! roles! in! regulating! cellJcell! adhesion,! cell! migration,!chromosomal!segregation!and!apoptosis!in!the!colonic!crypt.!(10)!It!plays!a!prominent! role! in! the! FAP! syndromes! and! its! variants! but! is! also! highly!prevalent!in!the!sporadic!tumours,!with!70J80%!of!colorectal!cancers!having!a! mutation! leading! to! inactivation! of! APC.! (10)! It! is! thought! that! APC!mutation! is! the! 1st! and! rateJlimiting! step! in! the! adenomaJcarcinoma!sequence!as!it!has!the!same!frequency!of!mutation!in!very!small!adenomas!as!it!does!in!advanced!carcinoma.!(9)!!A!major!suggested!role!for!APC!has!been!its!role!as!a!regulator!of!βJcatenin!protein! in! the! βJcatenin! dependent! Wnt! signaling! pathway.! When! APC! is!mutated! and! inactive! the! normal! pathway! is! disrupted! leading! to!accumulation! of! βJcatenin! in! the! cell,! resulting! in! a! downstream! effect! on!protoJoncogenes.!(11)!!




1.2.4!! p53!mutations!!According!to!the!Vogelgram,!the!final!steps!from!adenoma!to!carcinoma!are!controlled!by!the!p53!tumour!suppressor!gene.!Mutation!and!inactivation!of!p53! is! thought! to! stem! from! loss!of!heterozygosity! (LOH)!on!chromosome!17q! in! one! allele! with! a! somatic! mutation! in! the! remaining! gene.! This!combination!is!found!in!around!70%!of!colorectal!cancers.!(9;!14;!15)When!faced! with! cellular! stress! p53! activates! cell! cycle! arrest,! apoptosis! and!antiangiogenesis!pathways.!When!mutated!the!cell!does!not!perform!these!functions! under! maximal! stress! conditions! around! the! time! of! transition!from!adenoma!to!carcinoma.!(10)!!
!Figure!2:!The!various!rateJlimiting!and!rateJincreasing!steps!involved!in!the!development!of!colorectal!cancer!of!differing!aetiologies.!(10)!!
1.3! Genetic!Basis!of!the!Development!of!Colorectal!Liver!Metastases!!In!1889!the!English!surgeon!Stephen!Paget!published!his!seminal!“seed!and!soil”! hypothesis! to! explain! the!nonJrandom!pattern! of! tumour!metastases.!The! basis! of! his! theory! was! that! certain! tumour! cells! (the! seed)! have! a!
PM06CH20-Fearon ARI 6 D cember 2010 14:26





























Relative effects of germ-line mutations on tumor initiation and progression. (a) In sporadic colorectal
cancers (CRCs), both the initiation of a neoplastic lesion (e.g., the adenoma) and the progression of the
adenoma to an advanced lesion (i.e., the carcinoma) are rate-limiting steps because multiple independent
somatic mutations are required [e.g., adenomatous polyposis coli (APC) inactivation to initiate adenoma
formation and additional mutations for tumor progression]. (b) In the case of familial adenomatous polyposis
(FAP), germ-line inactivation of one APC allele markedly increases the formation of adenomas because
inactivation of one APC allele is a critical (rate-limiting) event in adenoma formation. However, adenomas
in patients with FAP presumably progress at a rate akin to that of sporadic adenomas because of the need to
acquire additional rate-limiting mutations for carcinoma development. (c) In the case of hereditary
nonpolyposis colorectal cancer, germ-line inactivation of one of the mismatch repair genes (e.g.,MSH2 or
MLH1), coupled with somatic inactivation of the remaining allele in an initiated lesion (e.g., an adenoma),
greatly increases the mutation rate and, subsequently, the rate of progression of adenomatous lesions to
carcinomas. Modified from Reference 51.
of stochastic somaticmutations in sequence ele-
ments thatmight be challenging for cancer cells
to replicate with high fidelity.
TUMOR-SUPPRESSOR GENE
DEFECTS IN OTHER INHERITED
PREDISPOSITIONS TO
COLON TUMORS
Although FAP patients develop hundreds to
thousands of adenomatous polyps, there are
other intestinal polyposis syndromes in which
patients manifest numerous nonadenomatous
lesions, such as hamartomatous polyps.Hamar-
tomatous polyps represent developmental mal-
formations that affect the epithelial glands and
the underlying lamina propria, where the mu-
cosal components are arranged abnormally but
the epithelial cells are not dysplastic. Several
of the syndromes pose an increased risk of GI
and/or non-GI cancers (Table 1).
Beginning in childhood, patients with the
juvenile polyposis syndrome ( JPS) develop
multiple hamartomatous polyps throughout the
GI tract, especially in the colon and the stomach
(11, 54). CRCs develop in approximately 60%
of JPS patients by age 60 (55). An increased
incidence of stomach cancer and, to a lesser
degree, small intestinal and pancreatic cancer
has been reported in JPS patients (56). Histo-
logically, juvenile polyps are characterized by
mucus-filled, cystically dilated glands, with an
abundant and often inflamed lamina propria
component. In a subset of patients and families
with JPS, there is a causative mutation in one
allele of the SMAD4 or BMPR1A TSGs (11,
54). Both genes encode proteins that function in
the transforming growth factorβ (TGF-β) sig-
naling pathway. The important contribution of
TGF-β pathway defects to the development of
sporadicCRC is discussed further below.Other
germ-line mutations that predispose to JPS in




























































specific!affinity!for!certain!organs!(the!soil).!He!concluded!that!a!metastasis!would!only!develop!if!the!‘seed’!and!the!‘soil’!were!compatible.!(16)!!It!has!been!shown!that!within!24!hours!of!entering!the!circulation!only!0.1%!of! tumour!cells!remain!viable!and!that! less! than!0.01%!survive!to!produce!metastases.!(17)!Human!tumours!are!made!up!of!a!heterogenous!population!of! cells! and! it! is! a! subJgroup! of! cells! within! it! that! have! the! biological!characteristics!that!give!them!metastatic!potential.!(18)!!There!are!a!number!of!rateJlimiting!steps!needed!for!a!tumour!to!produce!a!metastasis!as!depicted!in!the!figure!below.!!













!Figure!4:!The!regulation!of!metastases!from!Fidler!2003.!(16)!!The! microenvironment! of! different! organs! attracts! different! tumours.!Endothelial! cells! in! the! vasculature! of! the! organs! express! different! cell!surface! receptors! (19)! and! different! growth! factors! which! decide! which!tumours!develop!metastases!in!them.!(20)!It!has!been!hypothesised! that! in! the! future,! therapies! targeting!metastases!should!not!solely!focus!on!the!tumour!itself,!but!in!targeting!the!homeostatic!mechanisms!that!allow!and!promote!growth!of!the!metastasis.!!
1.4! Staging!of!Colorectal!Cancer!!In! 1932,! Cuthbert! Duke,! a! pathologist! working! at! St! Marks! Hospital! in!Harrow,!published!his!work!on!a!staging!system!for!rectal!cancer.!(21)!The!tumours!were!classified!into!Dukes!A!(tumour!confined!to!the!bowel!wall),!Dukes! B! (tumour! invading! through! the! serosa)! and! Dukes! C! (local! lymph!node! metastases).! Over! time! the! classification! was! subtlety! altered! with!Dukes! C! being! divided! into! C1! (lymph! node! involvement)! and! C2! (apical!node! involvement)! to! subJcharacterise! the! different! outcomes! seen.! (22)!The!staging!was!eventually!informally!adopted!for!tumours!of!the!rest!of!the!colon! and! not! just! the! rectum! and! the! stage! Dukes! D! was! also! added! to!signify!distant!metastases.!This!stage!was!not!in!the!original!article!because!as!a!pathologist,!Duke!worked!only!with!the!resected!rectal!specimens.!!
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and Kripke in 1977, from work with the
mouse B16 melanoma28. Using a modified
fluctuation assay of Luria and Delbruck22,
they showed that different tumour-cell
clones, each derived from individual cells
isolated from a parent tumour, vary
markedly in their ability to form pulmonary
nodules following intravenous inoculation
into syngeneic mice. Controlled subcloning
procedures showed that the observed diver-
sity was not a consequence of the cloning
procedure28 (FIG. 4).
To exclude the possibility that the
metastatic heterogeneity of B16 melanoma
cells might have been introduced as a result
of the lengthy cultivation, researchers stud-
ied the biological and metastatic hetero-
geneity of spontaneous tumours.
Melanomas were induced in mice by
chronic exposure to ultraviolet-B irradia-
tion and the tumour-promoting agent 
CROTON OIL. Tumour metastases were found
to differ greatly from each other and from
the parent tumour. In addition to differ-
ences in the number of metastases that
developed from each tumour, there was also
significant variability in the size and pig-
mentation of the metastases.Metastases to
the lymph nodes, brain, heart, liver and skin
were found in addition to lung metastases
— those growing in the brain were uni-
formly pigmented, whereas those growing
in other organs generally were not29.
The finding that cell subpopulations that
pre-exist within the same tumour have het-
erogeneous metastatic potential has since
been confirmed in many laboratories, in a
wide range of tumours of different histolog-
ical origin. In addition, studies that involved
young nude mice as models for metastasis of
human neoplasms have shown that several
human tumour lines and freshly isolated
tumours, such as colon carcinoma and
renal-cell carcinoma, also contain subpopu-
lations of cells with widely differing
metastatic properties30.
The clonal origin of metastases
Biological heterogeneity is found both within
a single metastasis (intralesional heterogene-
ity) and among different metastases (interle-
sional heterogeneity). This heterogeneity
reflects two main processes. These include
the selective nature of the metastatic process
and the rapid evolution and phenotypic
diversification of clonal tumour growth,
which results from the inherent genetic and
phenotypic instability ofmany clonal popu-
lations of tumour cells. Like primary neo-
plasms,metastases can have a unicellular or
multicellular origin. To determine whether
the hypothesis that the evolution of
tumours from the benign to the malignant
state could be the consequence of acquired
genetic instability24.
Metastatic heterogeneity
Cells with different metastatic properties
have been isolated from the same parent
tumour, indicating that not all the cells in a
primary tumour have the same potential to
disseminate (FIG. 3). To study this, tumour
cells are implanted subcutaneously, intra-
muscularly, directly into tissues or are
injected intravenously into mice. Tumours
are t en harv sted, and the recovered cells
are expanded in culture. The behaviour of
the expanded cells is compared to that of the
cells of the parent tumour to determine
whether the selection process enhanced
metastatic capacity. This procedure was
originally used to isolate the B16-F10 line
from B16 melanoma25. It has also been 
successfully used to derive metastatic cell
lines from many commonly studied experi-
mental tumours26.
In a second approach, cells are selected
for the development of a phenotype that is
associated with the metastatic sequence,
and then they are tested in animal models
to determine whether concomitant
metastatic potential is increased or
decreased. This method has been used by
Nicolson27 and Poste et al.26 to determine
whether properties such as adhesive charac-
teristics, invasive capacity, lectin resistance
and resistance to natural-killer cells are
required for metastasis.
One obvious criticism of these
approaches has been that the cancer cells
studied do not represent the progeny of a
unique subpopulation of tumour cells; they
are the progeny of tumour cells that can sur-
vive in a new microenvironment. The first
exp rimental proof for metastatic hetero-
geneity of neoplasms was provided by Fidler
cell-membrane-bound Na+, K+-ATPase)23.
The development of drug resistance was
compared between highly metastatic cells
from three different mouse tumours, cells
with low metastatic potential and non-
metastatic tumour cells isolated from the
same neoplasms. In all cases, cells with high
metastatic potential had a three- to seven-
fold increase in the rate of mutation (per
cell generation) at both genetic loci, com-
pared with their low metastatic but tumori-
genic cell controls23. These results support
Table 1 | Regulation of metastasis
Cell type Facilitation of metastasis Inhibition of metastasis
Tumour cells Production of growth factors and Antigenicity
their receptors
Production of angiogenic factors Inhibitors of angiogenesis
Motility, invasiveness Cohesion (E-cadherin)
Aggregation, deformability Tissue inhibitors of proteolytic 
enzymes
Specific cell-surface receptors and 
adhesion molecules
Host cells Paracrine and endocrine growth factors Tissue barriers
Neovascularization Blood turbulence, endothelial cells
Platelets and their products Tissue inhibitors of proteolytic 
enzymes







Survival in the circulation
Arrest
Extravasation
Evasion of host defence
Progressive growth




Figure 3 | Sequential steps in the
pathogenesis of cancer metastasis. Each
discrete step of metastasis (arrows) is likely to
be regulated by transient or permanent
changes in DNA, RNA or proteins. Most cancer
cells fail to undergo metastasis because of one
or more deficiencies (gaps between arrows).
Metastasis-competent cells (1) must perform a
variety of tasks. Cancer-cell metastasis can be
blocked at a variety of stages, including
deficiencies in invasion, or survival and
proliferation in the circulation (2, 3);  or multiple
deficiencies that prohibit metastasis (4 and 5).
Other tumour-cell phenotypes that preclude
metastasis include susceptibility to immune-
system attack (6) and an inability to grow at the
final metastatic site (7).
Chapter(1(
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Today,!the!Dukes!system!is!still! in!use,!but!the!gold!standard,!as!with!most!other!solid!tumours!is!the!TNM!system!initially!described!by!Pierre!Denoix!in!the!1940’s!in!Paris.!This!system!classified!the!tumour!by!the!extent!of!the!primary! tumour! (T),! the!position!of! involved! lymph!nodes! (N)!and!distant!metastases!(M).!The!American!Joint!Committee!for!Cancer!(AJCC)!produced!updated! guidelines! every! few! years! and! the! current! guidelines! were!published!as!the!7th!edition!in!2010.!(23)!!
!Table!2:!The!7th!edition!of!the!AJCC!TNM!staging!system!for!colorectal!cancer.!Adapted!from!Obrocea!et!al.!(23)!!The! complexities! of! the! TNM! stage! make! it! difficult! to! apply! to! clinical!practice!in!everyday!life.!For!this!reason!the!tumours!are!grouped!into!1!of!4!‘Stages’!in!order!that!management!plans!can!be!made.!
TMN'Stage ' 'Stage'Descrip@on'
Tx ! ! !Primary!tumour!cannot!be!assessed!
T0 ! ! !No!evidence!of!primary!tumour!
Tis ! ! !Carcinoma!inJsitu:!intraepithelial!or!invasion!of!lamina!propria!
T1 ! ! !Tumour!invades!submucosa!
T2 ! ! !Tumour!invades!through!muscularis!propria!
T3 ! ! !Tumour!invades!through!muscularis!propria!into!pericolorectal!Essues ! ! !!
T4a ! ! !Tumour!penetrates!to!the!surface!of!the!visceral!peritoneum !!
T4b ! ! !Tumour!directly!invades!or!is!adherent!to!other!organs!or!structures !!
!
Nx ! ! !Regional!lymph!nodes!cannot!be!assessed!
N0 ! ! !No!regional!lymph!node!metastases!
N1 ! ! !Metastases!in!1J3!regional!lymph!nodes!
N1a ! ! !Metastases!in!1!regional!lymph!node!
N1b ! ! !Metastases!in!2J3!regional!lymph!nodes!
N1c ! ! !Tumour!deposit(s)!in!the!subserosa,!mesentry,!or!nonJperitonealised!pericolic!or!periJrectal! !
! ! !Essues!without!regional!nodal!involvement!
N2 ! ! !Metastases!in!4!or!more!regional!lymph!nodes!
N2a ! ! !Metastases!in!4J6!regional!lymph!nodes!
N2b ! ! !Metastases!in!7!or!more!regional!lymph!nodes!
!
M0 ! ! !No!distant!metastases!
M1 ! ! !Distant!metastases!
M1a ! ! !Metastases!conﬁned!to!one!organ!or!site!




1.5! Diagnosis!and!Imaging!in!Colorectal!Liver!Metastases!!As!with!other!cancers!of! the!gastrointestinal! tract,! the!spread!of!colorectal!cancer! is! via! the! portal! vein! to! the! liver! before! entering! the! systemic!circulation.! Indeed,! the! liver!may! be! the! only! site! of! spread! in! 25J40%! of!patients!with!metastatic!disease.!(25;!26).!Around!25%!of!patients!will!have!liver! metastases! at! the! time! of! presentation! of! the! primary,! known! as!synchronous!disease,!while!up!to!50%!will!develop!metastases!in!the!liver!at!some!point!in!their!lifetime.!(27J29)Colorectal!cancer!is!one!of!few!cancers!where!metastatic! spread! is! not! an! absolute! contraindication! to!potentially!curable!disease.!Early!diagnosis!and!good!followJup!with!quality!imaging!is!essential!if!good!outcomes!are!to!be!achieved.!!
1.5.1!! Ultrasound!!Ultrasound! (US)! is! a!widely!available,!nonJinvasive!modality! that!does!not!involve!the!use!of!ionising!radiation.!Liver!metastases!tend!to!be!hypoechoic!on! US,! but! have! generally! nonJspecific! features! making! it! harder! to!accurately!categorise!them.!There!are!also!several!technical!limitations!with!ultrasound.!The!main! two!are! the!skill!and!experience!of! the!radiographer!and!the!body!habitus!of!the!patient!making!interpretation!difficult.!In!order!to!increase!the!sensitivity!of!the!test,!contrast!ultrasound!is!becoming!more!readily!available.!This!utilises!intravascular!microbubble!contrast!agents!to!enhance!the!texture!of!the!liver!during!the!arterial!phase.!This!makes!small!hypovascular! metastases! easier! to! diagnose.! Studies! have! shown! that! the!
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use! of! contrast! enhancement! has! increased! the! sensitivity! by! around!20%(30)! and! that! around! 97%! of! CT! detected! lesions! are! also! seen! on!contrast!US.!(31)!!
!Figure!6:!US!showing!liver!metastases.!The!image!on!the!left!in!unenhanced!with!no!contrast!in!the!portal!vein!(double!arrow).!After!contrast!enhancement!on!the!right!with!contrast!in!the!portal!vein!(double!arrow),!2!liver!metastases!are!now!clearly!visible!(single!arrows).!(31)!
1.5.2!! Computed!Tomography!!Computed! tomography! (CT)! is! the!most! commonly! used!modality! for! the!detection,! characterization! and! followJup! of! liver! lesions! including!colorectal!liver!metastases.!It!has!a!detection!sensitivity!of!between!60J90%!and!has!the!added!advantage!of!being!able!to!scan!the!full!thorax,!abdomen!and!pelvis!to!fully!stage!the!disease!and!detect!extraJhepatic!disease.!(32)!!
!Figure!7:!Colorectal!liver!metastases!as!seen!on!CT!in!the!portal!venous!phase.!(32)!
beam. When reexamination or examination in
another phase is necessary, a new injection of
contrast medium and repeated imaging after 4
minutes can be accomplished. With the exami-
nation technique described in our study, both
an immediate reexamination and an examina-
tion in different phases of liver perfusion are
possible. The amount of contrast medium need-
ed for the effect described in our study is lower,
thus reducing the cost of each examination.
Using the new ultrasonographic modality
described in our study, we were able to achieve
a detection rate for liver metastases significantly
higher than when using conventional ultra-
sonography. Although a comparison of echo-
enhanced ultrasonography and helical CT was
not the primary aim of this study, it should be
pointed out that echo-enhanced ultrasonogra-
phy did not surpass helical CT in detecting liver
metastases. Knowing that helical CT does not
detect all liver metastases means that a consid-
erable number of liver metastases remain
undetected.
Ultrasonography is a very specific tool; there-
fore, if it detects a lesion, it is not necessary to
reconfirm the results with CT.2,24 Whether this
ultrasonographic technique can replace CT for
detection of primary and secondary liver tumors
has yet to be evaluated.
When a lesion is detected by ultrasonography,
the next step should be to further characterize
the lesion or to obtain direct histologic proof.
Characterization of liver tumors can be accom-
plished by closely watching the perfusion kinet-
ics in the early phase and the vascular pattern on
contrast-enhanced ultrasonography.25–32 In this
respect, ultrasonography could replace other
more expensive and potentially harmful imag-
ing techniques.
Overall, we think that contrast-enhanced
WBHI is a new and promising imaging modality
that can make ultrasonography more reliable for
the detection of liver metastases. Further devel-
opment and use of this new modality will
J Ultrasound Med 20:509–515, 2001 513
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Figure 2. A, Liver metastases of pancreatic carcinoma shown on contrast-enhanced WBHI (thick-stemmed arrows). The portal v in filled with contrast
agent is also shown (thin-stemmed arrows). B, Conventional ultrasonography of the same region, which did not detect any metastases. The portal vein
without contrast agent is shown (arrows).
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Table 2. Detection Rates According to Size of the Lesion
No. of Lesions Detected
Helical Conventional Contrast-Enhanced
Lesion Size, cm CT Ultrasonography WBHI
≥2 34 26* 34*
<2 29 11† 27†
*P = .008.
†P < .001.
Table 3. Detection Rates According to Location of the Lesion
No. of Lesions Detected
Helical Conventional Contrast-Enhanced
Lesion Size, cm CT Ultrasonography WBHI
Left liver lobe 24 16* 24*
Right liver lobe,
segments 5 and 6 21 14* 21*
Right liver lobe,
segments 7 and 8 18 7† 16†
*P = .008.
†P < .004.
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ranged from 75% to 90% but at the expense of low specificity
reported to be as low as 68% [15,16,27–31]. Recognition of
potential false-positive findings due to benign lesions,
thrombus, or areas of focal fatty change is critical to avoid
over-staging. It is superior to othe imaging methods in the
detection of lesions measuring l ss han 2 cm in diameter
[32]. CTAP was usually reserved for imagi g candidates prior
to surgical hepatic resection as it provided an accurate
segmental localization of liv r metastases a d excelle t
depiction of liver vasculature. This invasive technique is less
routinely performed with the advent of MDCT and magnetic
resonance imaging (MRI) with liver-specific contrast agents,
which are as accurate in lesion detection but with much
lower false positive rates.
MRI
With the recent advances in MRI softwar , hardware and
image cquisition t chnique, MRI is now the most effective
imaging modality in detecting and characterizing liver
lesions [33]. MRI is particularly useful i characterizing
indeterminate lesions detected on other modalities such as
CT or unenhanced US and it can also identify some lesions
not visualized on either of these modalities. Its multi-planar
imaging capability can assist in surgical planning for liver
resection. The use of high-performance gradient systems
and phased array body coils provides higher signal to noise
ratio allowing thinner slices and higher resolution with
improved lesion detection. The introduction of faster
imaging sequences, such as T1-weighted spoiled gradient
echo and T2-weighted turbo spin echo have allowed rapid
image acquisition of the entire liver in a single breath-hold,
thus limiting motion artefacts. On T1-weighted images
colorectal liver metastases are typically of low signal
intensity with a rim surrounding a central area of even
lower signal intensity (doughnut sign) and on T2-weighted
ima es t ey are of ntermediate to high signal intensity and
sometimes associated with a hypointense halo (viable
tumour) surrounding central area of hyperintensity (tumour
necrosis, mucin) (target sign) [34] (Fig. 2).
Reported sensitivities for unenhanced MRI in the detec-
tion of liver metastases ranged between 66% and 83%
[35–37]. With the routine use of contrast enhancement, MRI
has sensitivity equivalent to CTAP with fewer false positives.
The two main types of MRI contrast agents used to improve
detection and characterization of liver lesions are extra-
cellular agents and tissue-specific agents. The most widely
used extracellular agents are paramagnetic chelates of
gadolinium; colorectal liver metastases appear as hypo-
intense masses that may have an enhancing rim on T1-
weighted images, similar to enhancement findings on CT.
Dynamic contrast enhanced imaging allows benign and
malignant lesions to be differentiated and may display
distinct features to suggest a more specific diagnosis.
Colorectal liver metastasis, a hypovascular lesion, on the
delayed arterial phase shows a cauliflower appearance with
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Figure 1 Portal venous phase CT. Colorectal metastasis
showing target sign.
Figure 2 T1 weighted MRI: colorectal metastasis showing enhancement on arterial phase (Fig. 2a) and washout on portal venous
phase (Fig. 2b).




1.5.3!! Magnetic!Resonance!Imaging!!If!considered!resectable!further!imaging!is!required.!NICE!guidelines!issued!in!November!2011!(CG131)!does!not!give!specific!guidance!on!which!extra!modalities!are!required!but!states!that!it!is!at!the!discretion!of!the!individual!MDT.!The!most!commonly!used!are!magnetic!resonance!imaging!(MRI)!and!positron!emission! tomography! (PET).!MRI! is!used! to! fully! characterise! the!metastases.! (33)! It! can! give! more! information! and! there! is! increased!sensitivity!after!the!use!of!contrast!agents.!(34).!!!





Metastases!!Surgery!for!colorectal!liver!metastases!has!made!considerable!progress!over!the!past! few!decades.! In! the!early! to!midJ90’s!surgery!with!curative! intent!was! only! considered! for! patients! meeting! the! most! stringent! of! criteria.!(38)These!were:!
• 1J3!unilober!metastases!with!preferably!metachronous!presentation!
• resectable!with!a!generous!margin!(R0)!!!Changes! in! chemotherapy! and! surgical! innovation! have! changed! the!landscape! and! current! guidance! is! that! all! patients! fit! enough! for! surgery!who! could! have! all! their! disease! removed! with! adequate! future! remnant!liver!(FRL)!volume!should!be!considered!for!surgery.!(24)!At!a!minimum,!a!future!liver!remnant!of!around!25%!(2!Couinaud!segments)!are!required!to!maintain! adequate! function.! If! there! is! impaired! hepatic! function,! then! a!greater! FRL! is! required! and! the! extent! of! chemotherapy! toxicity!must! be!considered.! If! the! planned! resection! is! extensive! and! a! borderline! FRL! is!predicted,! it! is! possible! to! perform! portal! vein! embolisation! (PVE)! before!resection!in!order!to!induce!hypertrophy!of!the!FLR!to!allow!the!resection!to!proceed! safely.! (39)Recently! the! need! for! microscopically! clear! margins!
intense peripheral enhancement (observed regularly in
lesions 43 cm). Ill-defined, peri-lesional enhancement of
the adjacent liver parenchyma is also a common finding.
Tissue-specific agents have the highest sensitivity for
metastases detection. Superparamagnetic iron oxides (SPIO)
is a negative contrast agent taken up selectively by the
reticuloendothelial system, where metastases appear as
high signal lesions against a background of low signal liver
parenchyma on T2-weighted images. Sensitivities with SPIO-
enhanced scan have been reported at 95% [37–39]. Limita-
tions of SPIO such as Endorem (Guerbet) include a long
infusion time (30min), which prolongs study time and may
be associated with significant side effects, such as low back
pain and hypotension that has been reported in 10–15% of
patients [38–43]. Mangafodipir trisodium (MnDPDP, TeslaS-
can, GE Healthcare) is a hepatocytes specific, positive
contrast agent, taken up by hepatocytes after intravenous
administration and the normal liver parenchyma shows
increased signal on T1-weighted images while metastases
are hypointense. MnDPDP-enhanced scan has been shown to
be more accurate than unenhanced MRI or spiral CT in the
detection of hepatic colorectal metastases, with sensitivity
of 90% [44]. MnDPDP is well tolerated with fewer side effects
than SPIO but lesion detection is limited in patients with
cirrhosis since liver enhancement in these patients is
reduced [45]. However, the lack of dynamic imaging
capability of these tissue-specific agents is a limitation.
Gadobenate dimeglumine (MultiHance, Gd-BOPTA; Bracco
Imaging SpA) contrast agent combines the properties of an
extracellular agent with those of a tissue-specific agent
allowing for both dynamic and delayed phase imaging to be
performed. Dynamic phase imaging is important for lesion
characterization while delayed phase imaging increases
sensitivity for lesion detection. Dynamic contrast enhanced
studies (precontrast, arterial phase, portal-venous phase
and equilibrium phase images), identical to non-specific,
extracellular gadolinium chelates are easily attainable with
Gd-BOPTA. In addition, 3–5% of Gd-BOPTA is also taken up by
normal liver parenchyma that shows enhancement on
delayed T1-weighted images while metastases remain
unenhanced. Gd-BOPTA sensitivity may not be as high as
that of SPIO, but it enables improved lesion characteriza-
tion, which is particularly important in cases where benign
and malignant lesions co-exist [38,46,47]. The main draw-
backs of MRI are relatively limited availability, higher cost
and longer study time. It is marred in patients who are
unable to breath-hold for more than 15 s.
Positron emission tomography (PET) and
PET-CT
18F-flourodeoxyglucose positron emission tomography (FDG-
PET) is a functional imaging technique that uses FDG
radiotracer to exploit the altered glucose metabolism and
preferential accumulation of radiotracer in tumour cells.
Earlier detection of liver metastases may be possible
because metabolic abnormalities usually precede anatomi-
cal changes in malignant tumours. The sensitivities of FDG-
PET in detection of colorectal liver metastases have been
reported to range between 94% and 100% [48–50]. In a
recent meta-analysis, comparing helical CT, 1.5-T MRI and
FDG-PET in the detection of colorectal liver metastases, the
sensitivities on a per-patient basis were 64.7%, 75.8% and
94.6%, respectively; FDG-PET was the most accurate
modality [2]. FDG-PET also has the advantage of surveying
the whole body for early extra-hepatic disease (peritoneal
metastases and lymph node involvement), tumour recur-
rence at post-surgical sites and monitoring treatment
response prior to morphologic changes [51,52]. FDG-PET
identified additional disease not seen on conventional
imaging resulting in a change in the clinical management
in 29% of patients [53]. FDG-PET is limited by its lack of
spatial resolution, inability to provide precise anatomic
localization of lesions and the inability to characterize
lesions. Computer registration software has been developed
to combine FDG-PET data with either CT or MRI images.
These methods are labour intensive and require registration
of datasets to be planned prospectively for accurate
interpretation. The recent introduction of PET-CT hybrid
scanners enable seamless and accurate fusion of the high-
resolution anatomic localisation of CT with the functional
data of FDG-PET. Images for CT and PET are acquired in a
single sitting, enabling optimal image registration and the
fusion images have higher capability of being manipulated.
This has improved tumour detection and more specifically,
lesion localisation [54]. Due to restricted availability and
high cost, FDG-PET and PET-CT should be used in selected
patients where the diagnosis is not clear following conven-
tional diagnostic modalities (Fig. 3).
US
Real-time trans-abdominal US offers a rapid, non-invasive
technique for screening patients with suspected colorectal
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Figure 3 Colorectal metastasis appearing as an area of
increased uptake on PET-CT.
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(R0)! has! also! been! challenged.! Pawlik! et! al! showed! that! although! the!difference! in! survival! outcome! was! better! in! R1! resections! (microscopic!evidence! of! tumour! at! the! resection! margin)! than! R2! resections!(macroscopic!evidence!of!tumour!at!the!resection!margin),!the!outcomes!for!R1! and!R0! (no!microscopic! tumour! at! the! resection!margin)!were! similar.!(40)!!An! alternative! to! surgical! resection! is! ablation! of! the! tumour.! There! are!multiple! modalities! of! this! including! radiofrequency! ablation! (RFA)! and!microwave! ablation! (MWA).! They! can! be! performed! at! the! time! of!laparotomy! or! percutaneously,! which! has! the! benefit! of! not! requiring!surgery.!Depsite!much!interest,!there!remains!little!high!quality!evidence!for!its!use.!The!American!Society!of!Clinical!Oncology! (ASCO)!advised! in!2009!that! in! the! absence! of! good! evidence,! that! surgery! remains! the! gold!standard.! (41)! The! use! of! percutaneous! ablative! techniques! is! often!reserved!for!unfit!patients!with!small!tumours.!To!date,!the!only!randomised!trial!is!the!CLOCC!trial!(EORTC!40004)!where!patients! with! irresectable! disease! were! randomised! to! receive!chemotherapy!+/J!RFA!(n=59/60).!Median!followJup!was!4.4!years!with!30!month!overall!survival!favouring!the!RFA!and!chemotherapy!arm!(61.7%!vs!57.6%)! with! a! median! progression! free! survival! of! 16.8! months! vs! 9.9!months!(p=0.025).!A!Cochrane!Review!in!2012!found!that!the!evidence!for!the!use!of!ablation!was!too!sparse!to!recommend!its!use!in!radical!treatment!of!metastases.!(42)!!
1.7! Chemotherapy!in!Colorectal!Cancer!!Around! 20J25%! of! patients! will! present! with! synchronous! disease! and! a!further! 20%!will! develop!metastases! at! some! point! after! resection! of! the!colorectal!primary.!The!National!Institute!for!Clinical!Excellence!(NICE)!has!produced! guidance! that! states! that! adjuvant! chemotherapy! should! be!considered! the! standard! of! care! in! all! highJrisk! Stage! II! and! all! Stage! III!
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cancers! following! resection! of! the! primary! tumour.! (24)! The! use! of!chemotherapy!in!operable!Stage!IV!disease!is!less!well!defined!at!present.!In! the! past! decade! there! has! been! a! significant! increase! in! the! survival! of!patients! with! Stage! IV! colorectal! cancer.! A! multiJcenter! review! suggested!that! improvement! in! survival! of! patients! diagnosed!with! colorectal! cancer!was! due! to! more! successful! treatment! of! metastatic! disease! by! a!combination!of! surgery!and!chemotherapy.! ! (43)! In! the!early!21st! century,!only! 5Jfluorouracil! was! available! for! the! treatment! of! colorectal! cancer.!Recently! there!have!been! significant!developments! and!multiple! agent! are!available.! Currently! the! mainstay! of! treatment! is! with! 5Jfluorouracil,!leucovorin,! oxaliplatin,! irinotecan,! capecitabine! and! the! monoclonal!antibodies! cetuximab! and! bevacizumab.! They! are! rarely! given! as!monotherapy! and! are! usually! combined! as! FOLFOX! (5JFU,! leucovorin! and!oxaliplatin),! FOLFIRI! (5JFU,! leucovorin! and! irinotecan)! or! XELOX!(capecitabine!and!oxaliplatin)!+/J!antibodies.!!
1.7.1!! Adjuvant!Chemotherapy!for!Advanced!Colorectal!Cancer!!In! a! large! phase! III! trial,! de! Gramont! et! al! randomised! 420! patients! with!unresectable! colorectal! liver! metastases! to! receive! 5JFU! +/J! oxaliplatin.!There!were! significant! increases! in! both! tumour! response! rate! (50.7%! vs!22.3%,! p=0.0001)! and! progression! free! survival! (9.0! vs! 6.2! months,!p=0.0003)! in! the! oxaliplatinJreceiving! group.! However,! there! was! no!difference!in!overall!survival!(16.2!vs!14.7!months,!p=0.12).!(44)!In!Europe,!several!largeJscale!trials!were!then!performed!to!assess!the!role!of!adjuvant!chemotherapy! in! resected! Stage! II! and! III! colorectal! cancer.! The! MOSAIC!study! included! 2,246! patients! who! received! 5JFU! and! leucovorin! +/J!oxaliplatin! following! resection.! This! showed! an! increase! in! disease! free!survival!(DFS)!and!overall!survival!(OS)!in!Stage!III!disease!(HR!0.8.!95%!C.I.!0.65J0.97,! p=0.023)! but! no! benefit! in! Stage! II.! (45)! Meanwhile,! the! PanJEuropean! Trials! in! Alimentary! Cancer! (PETACCJ3)! study! involved! 2,094!patients!randomised!to!either!receive!5JFU/LV!+/J!irinotecan.!No!difference!
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was!seen!in!either!5Jyear!DFS!or!OS.!(46)These!trials!have!led!to!the!use!in!the! United! Kingdom! of! oxaliplatin! as! the! first! line! agent! in! advanced!colorectal! cancer,! with! irinotecan! reserved! for! second! line.! In! the! United!States,!the!Irinotecan!Study!Group!performed!a! large!Phase!III!randomised!trial! to! assess! the! effect! of! irinotecan! in! palliative! patients.! 683! patients!were! randomised! to! either!5JFU/LV!alone;! irinotecan!alone;! or!5JFU/LV!+!irinotecan.! The! addition! of! the! irinotecan! to! the! 5JFU/LV! resulted! in!significant! increases! in!PFS!(7.0!vs!4.3!months,!p=0.004),! tumour!response!(39!vs!21%,!p=<0.001)!and!overall!survival!(14.8!vs!12.6!months,!p=0.04).!(47)! On! the! basis! of! this,! irinotecan! is! used! as! the! first! line! agent! in! the!United!States.!!
1.7.2! Adjuvant!chemotherapy!for!resectable!colorectal!liver!
metastases!!The! FFCD! AURC! 9002! trial! randomised! 173! patients! with! completely!resected! (R0)!hepatic!metastases! from!colorectal! cancer! to! followJup!with!observation! or! 6! months! of! adjuvant! chemotherapy! with! 5JFU/LV.! This!showed! an! increase! in! 5Jyear! DFS! in! the! chemotherapy! group! (33.5%! vs!26.7%,! p=0.028)! and! a! nonJsignificant! trend! towards! overall! survival!(51.1%!vs!41.1%,!p=0.12).! (48)!The!EORTC!0923! trial!attempted!a!similar!model! but! it! too! was! underpowered! and! no! significant! differences! were!shown.!A!later!paired!analysis!of!both!trials!confirmed!a!trend!of!increased!overall! survival! but! did! not! reach! significance! (62.2! vs! 47.3! months,!p=0.095).!(49)!!
1.7.3!! Neo:adjuvant!chemotherapy!for!colorectal!liver!metastases!!In! 2006! the! MAGIC! trial! firmly! defined! the! role! of! neoJadjuvant!chemotherapy! in! the!management! of! gastroJoesophageal! adenocarcinoma.!(50)! There! has! also! been! increasing! interest! the! potential! role! for! neoJadjuvant!chemotherapy!in!other!gastrointestinal!adenocarcinomas.!
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The!potential!benefits!include!reducing!tumour!volume!allowing!for!the!use!of! parenchymal! sparing! surgery,! the! potential! effect! on! micrometastases!reducing!the!risk!of!recurrence!and!allowing!for!observation!of!response!to!allow!more!personalized!therapy.!Rene!Adam!and!colleagues,!who!in!2004!retrospectively! analysed! the! outcome! of! 131! consecutive! patients! who!underwent! hepatectomy! following! neoJadjuvant! chemotherapy,! have!investigated! the! latter! extensively.! Following! chemotherapy! 58! patients!(44%)!had!evidence!of!disease!response,!39!(30%)!had!no!response!and!34!(26%)! had! evidence! of! disease! progression.! 5Jyear! survival!was! higher! in!those!who!responded!with!those!who!progressed!having!the!lowest!survival!(37%!vs! 30%!vs! 8%,! p=<0.0001).!Disease! free! survival! followed! a! similar!pattern!(21%!vs!20%!vs!3%,!p=0.02)!(51)!This!study!highlighted!the!poor!outcome!of!those!with!aggressive!disease,!namely!those!with!greater!than!4!metastases! that! progressed! on! chemotherapy! paving! the! way! for! these!patients!to!receive!second!line!therapy!rather!than!surgical!resection.!There! were! also! some! concerns! about! neoJadjuvant! chemotherapy.! The!primary!concerns!were!the!difficult!management!of!the!complete!response!and! whether! it! was! safe! to! give! chemotherapy! and! then! operate.! Several!small! studies! looked! to! address! this! issue.! They! confirmed! that! the!chemotherapy! was! generally! well! tolerated! with! an! acceptable! periJoperative!morbidity! of! between!21J50%!and! that! there!was!0%!operative!mortality.!(52J54)!!A!large!retrospective!study!of!1474!patients!who!either!underwent!surgery!alone! (n=169)! or! surgery! with! periJoperative! chemotherapy! (n=1302)!showed! that! there! was! an! increased! number! of! postJoperative!complications!in!the!chemotherapy!group!(37.2%!vs!24%,!p=0.006).!In!the!final! analysis,! neoJadjuvant! chemotherapy! did! not! lead! to! any! increase! in!overall!survival.!(55)!The! international!multiJcentre!EORTC!40983!(EPOC)! trial!was!designed! to!try!and!finally!answer!the!question!about!the!role!of!neoJadjuvant!and!periJoperative!chemotherapy!in!resectable!colorectal! liver!metastases.!(56)!364!patients!with!resectable!disease!were!randomised!to!either!surgery!alone!or!12! cycles! of! periJoperative! FOLFOX! (6! pre! and! 6! post).! The! primary!
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endpoint!was!3Jyear!progression!free!survival!with!secondary!endpoints!of!response!rate,!safety!and!overall!survival.!94%!of!those!in!the!chemotherapy!arm!received!at!least!one!preJoperative!cycle!with!78.6%!receiving!the!full!6!cycles.! Within! the! chemotherapy! arm,! 8! patients! (5%)! did! not! have! a!resection.!4!of!them!were!found!to!have!new!disease!and!4!had!progressed!while! on! chemotherapy.! There!was! a! high! dropout! rate! after! the! surgery.!Only!115!patients!(63.2%)!in!the!chemotherapy!arm!had!any!postJoperative!chemotherapy!with!only!43.9%!receiving!the!full!6!cycles.!At!analysis,!it!was!shown!that!of!those!patients!who!successfully!underwent!liver!resection,!the!3Jyear! PFS! was! significantly! higher! in! the! chemotherapy! arm! than! the!surgery! alone! arm! (36.2%! vs! 28.1%,! HR! 0.77,! 95%! C.I.! 0.6J1.0,! p=0.041).!There!was!also!a!trend!towards!longer!PFS!in!the!intentionJtoJtreat!anaylsis!(35.4%! vs! 28.1%,! HR! 0.79,! 95%! C.I.! 0.62J1.02,! p=0.058).! Following! the!publication!of!this!data,!the!study!was!used!to!define!the!standards!of!care!in!many! units,! particularly! in! the! United! Kingdom.! (57;! 58)More! recently!longerJterm! followJup! from! the! study! was! presented! at! the! American!Society!of!Clinical!Oncology!Meeting!in!2012.!With!a!median!followJup!of!8.5!years,! it! was! shown! that! nearly! half! the! patients! had! died! from! cancer!related!causes.!No!benefit!was!seen!in!overall!survival!(HR!0.87,!0.66J1.14,!p=0.303)!although!the!study!was!not!powered!for!this!secondary!endpoint.!There!was! a! nonJsignificant! increase! in! 5Jyear! and! overall! survival! in! the!chemotherapy!arm!(63.7%!vs!55%)!(187).!!Further!trials!are!ongoing!to!clarify!the!role!for!chemotherapy!in!resectable!disease.!In!the!United!States,!the!NSABP!Phase!III!trial!is!comparing!FOLFOX!and! FOLFIRI! in! liver! only! resectable! disease! treating! with! periJoperative!chemotherapy!(6!cycles!preJ!and!postJresection),!while!in!Europe!the!Phase!II!EORTC!40091!is!a!3Jarm!study!with!adjuvant!chemotherapy!for!resectable!disease.!The!use!of!cetuximab!in!resectable!disease!is!also!being!studied!in!the!New!EPOC!study,!which!has!closed!early!after!interim!data!analysis!and!is!currently!being!prepared!for!reporting.!
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!Figure!9:!Progression!free!survival!of!intentionJtoJtreat!and!all!resected!patients!in!the!EORTC! 40983/EPOC! trial.! There! was! a! significant! increase! in! PFS! in! the!chemotherapy!arm!but!at!median!followJup!of!8.5!months!there!was!no!significant!increase!in!overall!survival.!(56)!!!!
1.7.4!! Chemotherapy!for!irresectable!disease!!It! is! recognised! that! there! is! a! group! of! patients! who! are! initially!unresectable!at!presentation!but!may!become!resectable!after!a!response!to!chemotherapy.! (59)! The! rates! of! conversion! to! resectable! disease! vary!considerably! in! the! published! literature! and! rates! of! 6J60%! are! often!quoted.!(60)Adam!et!al!showed!that!patients!who!underwent!hepatectomy!following! conversion! chemotherapy!had! a! 5Jyear! survival! rate! of! 35J50%,!which! is! equal! to! those! who! were! resectable! at! presentation.! (61;! 62)!Folprecht! et! al! performed! a! systematic! analysis! of! 5! prospective! and! 1!retrospective! studies! that! showed! a! strong! correlation! between! higher!response!rates!with!chemotherapy!and!conversion!to!resectable!disease!and!resection.! (63)! Increasingly! aggressive! chemotherapy! regimes! have! been!used!to!achieve!higher!resection!rates.!(64)!
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were more frequent in patients who had received 
preoperative chemotherapy than in those who had received 
surgery alone, but remained within the range commonly 
noted after resection of liver metastases.1,3,18
In patients with advanced colorectal cancer, several 
studies have compared various chemotherapy regimens. 
However, very few prospective studies have investigated 
the combination of chemotherapy with surgery, and none 
has assessed perioperative chemotherapy. Most trials did 
not achieve the planned recruitment for multifactorial 
reasons (table 5).5–9 Although no level I evidence for a 
benefi t of combining chemotherapy and surgery was 
reported, individual opinions in favour of one or the 
other treatment option prevented some oncologists and 
surgeons from including patients in trials. This trial met 
its target accrual, thanks to an intercontinental 
collaboration involving Europe, Australia, and Hong 
Kong. Any future trial of this type is unlikely to have a 
surgery-only group.19
The primary objective of this trial was to assess 
perioperative chemotherapy in patients qualifying for 
resection of their metastatic disease. Had we assessed 
postoperative chemotherapy only, randomisation could 
have been done after successful resection of the 
metastases, and no patient would have been excluded 
because of ineligibility or unresectability. Because of the 
specifi c objective in our trial, patients had to be randomly 
assigned imperatively before surgery—ie, without any 
certainty that metastases assessed by imaging were 
actually resectable. This uncertainty represents a 
fundamental diﬃ  culty for all studies assessing 
preoperative treatment and makes such studies diﬃ  cult 
to undertake and analyse. For example, in the MAGIC 
(Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy) trial13 that assessed perioperative 
chemotherapy in gastric cancer, many randomised 
patients did not undergo complete resection of the 
cancer. In our trial, some metastases that were initially 
considered to be resectable at randomisation were 
actually more advanced and not resectable at surgical 
examination. Therefore we examined not only all 
randomised and eligible patients, but also those who 
received resection. All analyses were done according to 
the allocated treatment group (ie, including the patients 
who did not receive the allocated treatment). The number 
of patients who fi nally underwent resection was much 
the same in both treatment groups.
The principal reason for non-resectability was more 
advanced disease than was expected, which was probably 
mostly due to a discrepancy between imaging and 
surgical examination. However, we noted a trend towards 
fewer failures to resect in the perioperative chemotherapy 
group than in the surgery group because of extensive 
disease, and a higher rate of failures to resect because of 
refusal or poor condition of the patient, which could 
introduce a selection bias. Results of progression-free 
survival in resected patients might be of interest in view 
Figure 2: Progression-free survival by treatment group
(A) All randomly assigned patients. (B) All eligible patients. (C) All resected patients. For all patients randomly 
assigned and those who were eligible, no surgery or no resection were regarded as events for the primary endpoint 
of progression-free survival. PeriOpCT=perioperative chemotherapy with fl uorouracil or leucovorin, and oxaliplatin.

























































































































Number of patients at risk
Surgery
PeriOpCT
Number of patients at risk
Surgery
PeriOpCT
All randomly assigned patients
All eligible patients
All resected patients
HR 0·79 (95·66% CI 0·62–1·02); p=0·058
HR 0·77 (95·66% CI 0·60–1·00); p=0·041
HR 0·73 (95·66% CI 0·55–0·97); p=0·025
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!Figure! 10:! Overall! survival! in! patients! undergoing! hepatectomy! following! neoJadjuvant!chemotherapy!for!initially!unresectable!disease.!(61)!!!The! GERCOR! study! by! Tournigand! et! al! in! 2004! compared! the! use! of!FOLFOX!and!FOLFIRI!in!unresectable!disease.!Patients!were!randomised!to!receive!either!FOLFOX!or!FOLFIRI!until!progression!of!disease!or!toxicity!at!which!point!they!were!switched!to!receive!the!other!regime.!!Response!rates!of!54J58%!were!seen!in!metastases!at!any!site.!There!was!no!difference!in!the!PFS!in!either!group!as!a!first!line,!but!in!those!who!switched!to!FOLFOX!increases! in! PFS! were! seen! (4.2! vs! 2.5! months,! p=0.003).! There! was! no!difference! seen! in! overall! survival.! Resection! was! achieved! in! 9%! (10!patients)!who! received! FOLFIRI! initially! followed! by! FOLFOX! and! in! 22%!(24!patients)!in!those!who!initially!received!FOLFOX!followed!by!FOLFIRI.!A!complete!resection!(R0)!was!achieved!in!7J13%.(65;!66)Following!this!work!a!major! systematic! review! of! irinotecan! and! oxaliplatin!was! published! by!the!UK!Health!Technology!Assessment!Agency.! It! concluded! that! resection!rates! in! FOLFIRI! were! 9J35%! and! in! FOLFOX! 7J51%.(67)! These! studies!further!confirmed!the!position!of!using!FOLFOX!as! firstJline!therapy! in!the!United!Kingdom.!The!Gruppo!Oncologico!Nord!Ovest!(GONO)!performed!a!randomised!Phase!III! trial! to! investigate! the! use! of! triplicate! therapy.! 244! patients! were!randomised!to!receive!either!FOLFOXIRI!or!FOLFIRI.!A!good!response!rate!was!seen!with!the!triplicate!therapy,!with!the!R0!resection!rate! in!patients!with! liver! only! metastases! being! 36%! as! opposed! to! 12%! with! FOLFIRI!(p=0.017).! (68)! However,! there! were! significant! increases! seen! in! sideJ
At multivariate analysis, 4 factors were significantly
associated with decreased survival (Table 5): tumor progres-
sion (P ! 0.0001), elevated preoperative serum CA 19–9
(P ! 0.0001), number of resected metastases (P ! 0.001),
number of lines of chemotherapy (P " 0.04). All but the
latter factor were also significant for disease-free survival
(Table 5).
DISCUSSION
This study shows that liver resection combined with pre
and postoperative chemotherapy offers the possibility of
long-term survival to patients with multiple colorectal metas-
tases. This benefit can be obtained, only when metastatic
disease is controlled by chemotherapy prior to liver surgery.
Tumor progression while on preoperative chemotherapy is
associated with poor outcome, even when hepatectomy is
potentially curative. Therefore, disease control before surgery
is crucial to prolonged disease-free survival.
Although usually associated with a oor outcome, liver
resection for multinodular metastases was used as a model to
test the influence of response to neoadjuvant chemotherapy
on outcome. In the 1980s, the presence of more than 3 lesions
was considered a contraindication to liver surgery.9,22 More
recently, this dogma was overcome because better results
were obtained with rising expertise in liver surgery, decreas-
ing operative mortality, and higher efficacy of chemothera-
py.23,24 However, there is still no agreement on the real
benefit to perate such pa ients a d on the strategy to adopt
for an optimized outcome.
In our practice, the number of metastases has never
been a contraindication to surgery provided that a complete
resection was technically possible, leaving at least 30% of
nontumoral liver parenchyma behind, to prevent the risk of
postoperative liver failure. Five-year survival after liver re-
s ctio was 28% in our p tient . This rate compares favor-
ably to other surgical series reporting no 3-year survivors at
all9 or more recently, a 23% 5-year survival rate.23,25 The
median survival of 30 months in our study population also
compares favorably to that of 20 months observed with the
currently most effective chemotherapy regimens alone.15,26
However, the overall survival rate was lower than the 51%
5-y ar survival of our patients resected for less than 4 metastases
during the same period (data not shown). Nevertheless, as
long-term survival is almost impossible to obtain with the sole
use of chemotherapy,1,27 liver resection is the only means to
offer these patients a real chance of long-term remission.
FIGURE 4. Disease-free survival in
relation to the response to preoper-
ative chemotherapy.
FIGURE 3.Overall survival in relation
to the response to preoperative che-
motherapy.
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effects,! particularly! peripheral! neurotoxicity! (0%! vs! 19%,! p=<0.001)! and!neutropenia! (28%! vs! 50%,! p=<0.001).! Due! to! the! increased! sideJeffect!profile,!triplicate!therapy!is!not!used!routinely!in!the!first!line!treatment.!!
1.8! Biological!Agents!in!Metastatic!Colorectal!Cancer!!The! monoclonal! antibodies! to! epidermal! growth! factor! receptor! (EGFR),!cetuximab! (Erbitux®)! and! panitumumab! (Vectibix®),! and! to! vascular!endothelial! growth! factor! (VEGF),! bevacizumab! (Avastin®)! have! recently!been!the!subject!of!much!interest!in!the!treatment!of!irresectable!metastatic!colorectal!cancer.!!These!therapies!do!however!have!their! limitations.! It!has!been!shown!that!patients!with! a!mutation! in! the!KRAS! (Kirsten! rat! sarcoma)! oncogene! are!resistant!to!treatment!with!antiJEGF!monoclonal!antibodies.!(69)!Currently!as! the! KRAS! status! of! the! primary! tumour! is! similar! to! the! metastases,!testing!of! the!paraffinJembedded!primary!tumour!can!be!used!to!predict! if!there!is!any!role!for!antiJEGF!therapy!in!an!individual!patient.!(70)!!
1.8.1! Cetuximab!!Tabernero!and!colleagues!performed!a!Phase!II!trial!assessing!the!potential!for! a! role! of! cetuximab! in! addition! to! standard! chemotherapy! in!unresectable!metastatic!colorectal!cancer.!In!the!clinical!arm!of!the!study!43!patients! received! cetuximab! in! addition! to! FOLFOX.! The! overall! tumour!response! rate! was! 72%! and! median! overall! survival! was! 30! months.! 10!patients! (23%)! were! downstaged! enough! to! be! considered! suitable! for!resection.!Importantly,!the!drug!was!well!tolerated!and!caused!no!extra!side!effects.!(71)!!!The!BOND!study!randomised!329!patients!who!had!previously!been!treated!with!irinotecan!to!therapy!with!cetuximab!+/J!irinotecan.!The!combination!group!showed!significantly!higher! tumour!response!rate!(22.9%!vs!10.8%,!
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p=0.007)! and! a! nonJsignificant! increase! in! median! survival! (8.6! vs! 6.9!months,!p=0.48).!(72)!The!OPUS!trial!was!a!Phase!II!trial!comparing!FOLFOX!+/J!cetuximab!in!337!patients! with! unresectable! colorectal! liver! metastases.! Higher! response!rates!were!seen!in!the!cetuximab!group!in!keeping!with!other!trials!(45.6!vs!35.7%).!The!EPIC! trial!was!a! large!randomised!Phase! III!of!1298!patients!who!had!failed!therapy!with!oxaliplatin.!Patients!were!allocated!to!receive!irinotecan!+/J! cetuximab.! Significant! increases! in! tumour! response! rate! (16.4%! vs!4.2%,! p=<0.0001)! and! progression! free! survival! (4.0! vs! 2.6! months,!p=<0.0001)!were!seen!with!cetuximab!therapy.!(73)!!The! CRYSTAL! trial! randomised! 1217! patients! to! receive! either! FOLFIRI!(n=609)!or!FOLFIRI!+!cetuximab!(n=608).!In!keeping!with!previous!studies,!patients!receiving!cetuximab!had!a!significant!increase!in!tumour!response!rate! (46.9%! vs! 38.7%,! p=0.005)! and! progression! free! survival! (8.9! vs! 8.0!months,! p=0.036).! (69)! A! pooled! analysis! of! the! results! of! the! OPUS! and!CRYSTAL!trials! to!give!more!power!showed!significant! increases! in!overall!survival,! response! rate! and! progression! free! survival! in! the! cetuximab!groups.!(74)!
!Figure!11:!Overall!survival!in!pooled!analysis!of!the!OPUS!and!Crystal!trials.!Those!receving!cetuximab!had!a!significantly!increased!OS!(p=0.0062).!(74)!
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Fig. 4. Overall survival in the analysis of pooled data from patients with KRAS wild-type tumours. Shown are Kaplan–Meier survival plots of
overall survival for the pooled patient population: according to treatment arm (A) and according to treatment arm and tumour BRAF mutation
status (B). CT = chemotherapy (FOLFIRI/FOLFOX-4).
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!A! more! recent! Phase! II! trial! (CELIM)! comparing! the! use! of! cetuximab! in!combination!with!either!FOLFOX!or!FOLFIRI!reported!high!response!rates!of!68%!and!57%!respectively.!There!was!no!nonJcetuximab!group!in!this!study!which!makes! the! results! harder! to! interpret.! (75)! The!UK!MRC!COIN! trial!was!a!large!(n=1630)!study!comparing!the!use!of!cetuximab!in!combination!with!FOLFOX.!Although!there!was!an!increase!in!response!rate,!no!difference!was!seen!in!overall!survival!meaning!they!could!not!recommend!the!use!of!cetuximab!in!first!line!therapy.!(193)!!







Trial/Author ) )Agent ) ) ) )Outcome)
MOSAIC ' '5)FU+/)'oxalipla4n ' 'Increase'in'DFS'and'OS'in'Stage'III'cancer'with'oxalipla4n'
PETACC)3 ' '5)FU+/)'irinotecan ' 'No'diﬀerence'in'groups'
'
Adjuvant)Chemotherapy)for)Colorectal)Liver)Metastases'
Trial/Author ) )Agent ) ) ) )Outcome'
FFCD'AURC'9002 '5)FU'or'observa4on ' 'Increase'in'5)year'DFS'in'treatment'group'
EORTC'0923 ' '5)FU'or'observa4on ' 'No'diﬀerence'(under'powered)'
'
Neo>adjuvant)Chemotherapy)for)Colorectal)Liver)Metastases)
Trial/Author ) )Agent ) ) ) )Outcome)
EORTC'40983 ' 'Surgery+/)'FOLFOX ' 'Increased'3)year'PFS.'No'OS'beneﬁt'in'chemotherapy'arm'
'
Chemotherapy)for)Irresectable)Disease)
Trial/Author ) )Agent ) ) ) )Outcome'
De'Gramont ' '5)FU+/)'oxalipla4n ' 'Increased'tumour'RR'and'PFS'in'oxalipla4n'group'
GERCOR ' 'FOLFOX'or'FOLFIRI'(cross)over) 'No'diﬀerence'in'PFS'
' ' ' ' ' ' ' 'Increase'in'PFS'in'those'switched'to'2nd)line'FOLFOX'
' ' ' ' ' ' ' 'Higher'resec4on'rate'with'FOLFOX'
GONO ' ' 'FOLFIRI'or'FOLFOXIRI ' 'Higher'response'and'resec4on'rate'with'triple)therapy'
Irinotecan'Study '5)FU+/)'irinotecan ' 'Increase'PFS,'RR'and'OS'in'combina4on'group'
Group'(USA) ' 'or'irinotecan'alone ''
'
Biological)Agents)in)MetastaCc)Colorectal)Cancer)
Trial/Author ) )Agent ) ) ) )Outcome)
Tabernero ' 'FOLFOX'plus''cetuximab 'RR'of'72%.'Drug'well'tolerated.'
BOND ' ' 'Irinotecan'+/)'cetuximab 'Increased'RR'with'cetuximab'
OPUS ' ' 'FOLFOX'+/)'cetuximab 'Increased'RR'with'cetuximab'
EPIC ' ' 'Irinotecan'+/)'cetuximab 'Increased'RR'and'PFS'with'cetuximab'
CRYSTAL ' 'FOLFIRI'+/)'cetuximab' 'Increased'RR'and'PFS'with'cetuximab'
Hurwitz ' 'FOLFIRI'+/)'bevacizumab 'Increased'median'survival,'PFS'and'RR'with'bevacizumab'
Tree)1/Tree)2 ' 'Oxalipla4n'+/)'bevacizumab 'Increased'RR'with'bevacizumab'and'FOLFOX'
NO16966 ' 'FOLFOX/XELOX'+'bevacizumab'or'placebo 'Increased'PFS''with'bevacizumab'




1.9! Assessment!of!Response!to!Chemotherapy!!In! patients! receiving! chemotherapy! in! the! neoJadjuvant! setting,! it! is!important! that! there! is! an! accurate! assessment! of! how! successful! the!therapy!has!been.!As!with!most! solid! organ! tumours,! the! response! can!be!defined! preJoperatively! by! imaging,! or! postJoperatively! by! histological!examination!of!the!specimen.!!
1.9.1!! Radiological!Response!!Multiple! different! scoring! systems! to! predict! radiological! response! have!been!previously!described.!To!overcome!the!difficultly!of!multiple!systems!in! a!multiJnational! task! group!was! set! up! in! 1994! including! the!European!Organization! for!Research!and!Treatment!of!Cancer! (EORTC),! the!National!Cancer!Institute!(NCI)!of!the!United!States!and!the!National!Cancer!Institute!of!Canada!Clinical!Trials!Group.!In!2000!they!published!their!guidelines.!The!Response! Evaluation! Criteria! in! Solid! Tumours! (RECIST)! criteria! was!intended! to! standardise! estimation! of! response! rate! to! chemotherapy.!(80)This! scoring! system! uses! the! size! of! the! lesions! preJ! and! postJchemotherapy!to!define!the!degree!of!response.!!
!! ! Table!3:!RECIST!criteria!for!tumour!response!to!chemotherapy!!The!criteria!were!updated! in!2009!to!Version!1.1! that!were!essentially! the!same!but!used!different!size!criteria!for!selecting!target!lesions.!
Response ' 'Change'in'size'of'lesion'
Complete ( ((Lesions(disappear(
Par1al ( ( (>30%(reduc1on((
Stable ( ( (No(change(
Progressive ( (>20%(increase(
Response'to'Chemotherapy ' 'Deﬁni6on'of'Response ' '58year'overall'survival'
Complete ( ( ( (No(residual(cancer(cells ( ( (75%(
Major ( ( ( ( (1D49%(residual(cancer(cells ( ( (56%(
Minor ( ( ( ( (>50%(residual(cancer(cells ( ( (33%(
Grade ' '%'of'hepatocytes'aﬀected'
Absent( ( (<5%(
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!Figure! 12:! KaplanJMeier! curves! showing! overall! survival! by! pathological! response! to!chemotherapy!and!histology!of! (A)!complete!response,! (B)!major!response!and!(C)!minor!response.!(84;!85)!!It! was! clearly! shown! that! there! was! a! significant! correlation! between!pathological!response!rate!and!overall!survival.!This!finding!was!confirmed!in! a! European! paper! in!which!Adam! et! al! found! a! 76%!5Jyear! survival! in!those!with!a!complete!response!to!chemotherapy!compared!to!45%!in!those!without.!(85)!!These! studies! highlight! the! potential! benefit! of! neoJadjuvant! systemic!chemotherapy! for! those! patients! with! colorectal! liver! metastases,!particularly!those!who!have!a!good!response!to!treatment.!
1.10! Mechanism!of!Action!of!Chemotherapeutic!Agents!!
1.10.1!!!5:Fluorouracil!!5JFluorouracil!(5JFU)! is!a! fluoropyrimidine!antiJmetabolite.! Its!structure! is!an! analogue! of! uracil! with! the! substitution! of! a! fluorine! atom! in! place! of!
Hepatectomy Characteristics
CPRwas found at first hepatectomy in 20 patients (69%) and at
repeat hepatectomy in nine patients (31%; 24% at second and 7% at
third hepatectomy).
Portal vein embolization was performed before hepatectomy in
three patients to increase the volume of the future remnant liver
(Table A1, online only).18 For two patients of the CPR group the
selected hepatic resection constituted the second step of a two-
stage resection.19
The 60-daymortality ratewas 0%, and hepatic and general com-
plications were observed in 16% and 24% of patients with CPR,
respectively. Chemotherapy was continued postoperatively in 82%
and 84% of patients with and without CPR, respectively (P! .75).
Pathology Details
Compared with patients without CPR, patients with CPR had
fewermetastases in the resection specimen (mean, 1.9 v 3.4;P! .005)
with a smaller maximum tumor size (mean, 13.0 v 43.0 mm; P" .001;
Table A2, online only). A margin-free resection (R0) was performed in
72%ofpatientswithCPRversus56%ofpatientswithoutCPR(P! .18).
Survival
Overall 3- and 5-year survivals for patients with CPR were 91%
and 76%, respectively, and were significantly higher when compared
with patients without CPR (61% and 45%, respectively; P ! .004;
Fig 1). Ten-year survivals were 68% and 29%with and without CPR,
respectively. Disease-free survivals were also different between both
groups (69% and 19% at 5 years; P" .001; Fig 2).
A comparison of both patient groups solely considering pa-
tients with liver-only metastases revealed 5-year overall survival
rates of 65% and 44% (P ! .05) with and without CPR (Fig 3).
After a median follow-up of 52.2 months (range, 1.1 to 193.0
months), less recurrences occurred in patients with CPR (41% v
62% for patients without CPR; P! .03). Hepatic recurrences were
less frequent in theCPR group (17% v 57%, respectively;P! .003).
Isolated extrahepatic or combined intra- and extrahepatic recur-
rences both occurred in 42% of patients with CPR. Repeat hepatec-
tomy was performed in six patients, two of whom also underwent
extrahepatic disease resection. Three additional patients only had
resection of extrahepatic disease recurrence. At last follow-up, 20
patients with CPR are alive disease-free (69%), of whomninemore
than 5 years and 5 more than 10 years after hepatectomy. Two
patients are alive with disease (7%) and seven patients (24%) have
died from recurrence.
Analysis of Predictive Factors
Univariate analysis identified seven preoperative variables with
statistical difference (P ! .10) between both groups (Table 2). At
multivariate analysis, four of the univariate factors were found to be
independent predictive factors ofCPR: age! 60 years,maximumsize
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Patients at risk Total 1 yr 3 yrs 5 yrs 6 yrs 8 yrs 10 yrs
CPR 29 25 19 11 11 8 5
No CPR 738 545 222 104 71 36 20
Fig 1. Overall survival curves (Kaplan-Meier) of patients with and without
complete pathologic response (CPR).
0

















1 2 3 4 6 985 7 10
CPR (N = 28)
No CPR (N = 685)
69%69%
Patients at risk Total 1 yr 3 yrs 5 yrs 6 yrs 8 yrs 10 yrs
CPR 28 23 15 9 9 8 5
No CPR 685 349 130 70 46 26 15
19%
11%
Fig 2. Disease-free survival curves (Kaplan-Meier) of patients with and without
complete pathologic response (CPR).
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Patients at risk Total 1 yr 3 yrs 5 yrs 6 yrs 8 yrs 10 yrs
CPR 20 17 13 6 6 4 2
No CPR 585 456 202 101 71 39 27
Fig 3. Overall survival curves (Kaplan-Meier) of patients with liver-only metas-
tases with and without complete pathologic response (CPR).
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hepatectomy was performed in 212 patients (70%), and radiofre-
quency ablation was concomitantly performed in 100 patients
(33%). The median tumor size was 2.5 cm (range, 0.1 to 13.0 cm),
and the median number of tumors was two (range, one to 21
tumors). All patients underwent macroscopically curative resec-
tion, but 31 patients (10%) had positive surgical margins. The
median follow-up period was 25.0 months (range, 0.3-114.5
months). Three patients (1%) died within 30 days of surgery, eight
patients (3%) died within 60 days of surgery, and 11 patients (4%)
died within 90 days of surgery.
Pathologic Response
Pathologic response was ev luated in the specimens of 271 pa-
tients (89%). Twenty-five patients (9%) had a complete response, 97
patients (36%) had a major response, and 149 patients (55%) had a
minor response. Therewere very few tumornoduleswithno response
(100% residual cancer), and, in fact, only six of 149 (4%) patients
showed ! 10% resp nse. Therefore, all patients with 0% to 50%
response were included in the minor response group.
Predictor of Survival
Survival curves foreachresponsegroupare illustrated inFigure2.
Cumulative1-, 3-, and5-yearoverall survival ratesby responsewere as
follows: complete response, 100%, 100%, and 75%; major response,
95%, 69%, and 56%; and minor response, 91%, 58%, and 33%,
respectively. The survival differences between complete and major
response (P ! .037) and between major and minor response
(P! .028) were both statistically significant by log-rank test.
Results of univariate a d multivariate analyses of the predictors
of survival are shown in Table 1. Factors significantly associated with
worse survival were DFI less than 1 year, fluoropyrimidine and
irinotecan-based chemotherapy as opposed to fluoropyrimidine
and oxaliplatin with bevacizumab-based chemotherapy, concom-
itant radiofrequency ablation, multiple tumors, and major or
minor response as opposed to complete response. Tumor size
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Fig 2. Overall survival curves by the degree of pathological response.
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The!enzyme!thymidylate!synthase!(TS)!is!essential!in!producing!thymidylate!for! DNA! replication! and! repair.! It! involves! the! reductive! methylation! of!deoxyuridine!monophosphate! (dUMP)! to! deoxythymidine!monophosphate!(dTMP)!with! a! reduced! folate,! CH2THF,! as! the!methyl! donor.! FdUMP,! as! a!metabolite!of!5JFU,!in!conjunction!with!CH2THF,!forms!a!suicide!blockade!of!the!nucleotide!binding!site!on!thymidylate!synthase!preventing!dUMP!from!binding! and! being! converted! to! dTMP.! The! resulting! reduction! in! the!amount!of!thymidylate!available!causes!cell!death!by!reducing!the!amount!of!thymine!available!and!causing!a!thymineless!cell!death.!The!function!of!the!enzyme!thymidine!kinase!(TK)!to!produce!thymidylate!has!been!suggested!as! a! potential! source! of! resistance! to! 5JFU.! (87)! ! The! reduced! folate,!leucovorin,! is! often! given! in! combination! with! 5JFU! to! help! increase! its!potency.!!The! remaining! two! active! metabolites,! FUTP! and! FdUTP! have! been!implicated!in!cell!death!by!causing!direct!damage!to!DNA!and!RNA!by!misJincorporation!into!them!causing!disruption!of!the!strands.!(88,!89)!The!DNA!repair!enzyme!uracilJDNAJglycosylase!(UDG)!is!ineffective!due!to!the!levels!of!metabolites!and!this!leads!to!further!DNA!strand!damage!and!ultimately!cell!death.!(90)!!
1.10.2!!!Irinotecan!!Irinotecan! is! an! analogue! of! camptothecin,! a! naturally! occurring! cytotoxic!extracted!from!Camptotheca(acuminate!and!was!developed!as!an!antiJcancer!drug!in!the!early!1970’s.!(91)!It!is!a!Topoisomerase!1!inhibitor!that!binds!to!the! DNA/Topoisomerase! 1! complex! during! DNA! replication! preventing!resealing!of!!single!strands!during!DNA!coiling!and!uncoiling.!This!results!in!doubleJstrand!DNA!breaks,!leading!to!apoptotic!cell!death.!(92)!
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!Figure!14:!The!metabolism!of!Irinotecan!!Irinotecan!is!a!proJdrug!that!is!converted!to!the!active!metabolite!SNJ38!via!human! carboxylesterases! CES1! and! CES! 2.! The! cytochrome! P450! enzyme!CYP3A4!also! converts! irinotecan! to! its! inactive!metabolite!APC.!The!active!SNJ38! is! inactivated! to! SNJ38G! by! glucuronidation! via! the! enzyme! UDPJglucuronosyltransferase.!The!most! active! form! is! the!UGT1A1!enzyme!and!interindividual! variation! in! expression! of! this! enzyme,! due! a! relatively!common! polymorphism,! has! been! linked! to! differing! responses! to,! and!toxicity!from,!the!drug.!(93)!Its!major!toxicity!and!side!effects!are!diarrhoea!and!neutropenia!although!hepatotoxicity!is!increasingly!recognised.!!!
1.10.3!!!Oxaliplatin!!PlatinumJbased! chemotherapy! agents! have! been! in! use! for! over! 30! years.!Several! analogues! have! been! developed! to! overcome! issues! surrounding!drug! resistance! and! toxicity.! Oxaliplatin,! a! platinumJbased! compound!containing!a!diaminocyclohexane!(DACH)!ring,!has!a!wide!spectrum!of!antiJ
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tumour! activity! and! is! currently! used! as! firstJline! treatment! for! the!management!of!metastatic!colorectal!cancer.!
!Figure!15:!The!metabolism!of!Oxaliplatin!!The!cytotoxic!activity!of!oxaliplatin!is!from!direct!DNA!damage.!It!undergoes!biotransformation! in( vivo! into! a! number! of! metabolites! that! all! contain! a!DACH! ring.! (94)!DACHJPt!DNA!adducts! are! formed!by! crossJlinking! of! the!DNA! strands.! There! seems! to! be! a! preference! for! nuclear! DNA! over!mitochondrial!DNA.! (95)!These!primary! lesions!block!DNA!replication!and!transcription!causing!cell!damage!leading!to!cell!death!and!apoptosis.!!Resistance! to! oxaliplatin! is! thought! to! stem! from! different! mechanisms!involved! in! DNA! repair.! (96)! These! include! nucleotideJexcision! repair!(NER),! base! excision! repair! (BER),! mismatch! repair! (MMR)! and! double!strand! break! repair.! This! area! is! currently! the! focus! of! much! research! to!help!identify!possible!pathways!of!resistance!and!future!therapies.!(97)!!!
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1.10.4!!!Biological!Agents!!!In!order!to!continue!to!grow,!tumours!require!the!development!of!their!own!blood!supply.!As!they!enlarge,!they!reach!a!point!at!which!they!can!no!longer!grow! without! an! independent! supply.! At! a! critical! point! there! is! relative!tissue!hypoxia!that!causes!increased!expression!of!transcription!factors!such!as! hypoxia! inducible! factor! 1α! (HIFJ1α)! which! upregulates! VEGF! and!resulting!angiogenesis.!(98)!Expression!of!EGF,!transforming!growth!factor!β! (TGFJβ) and! interleukins! 1! and! 6! (ILJ1,! ILJ6)! have! been! shown! to! be!involved! in! the! expression! of! VEGF.! (99)! Basic! understanding! of! these!pathways!has! led! to! the!development!of!monoclonal!antibodies! to!directly!inhibit!them!in!patients!with!cancer.!!
1.10.5!!!Cetuximab!!Cetuximab! is! a! chimeric! monoclonal! antibody! that! inhibits! the! Epidermal!Growth! Factor! Receptor! (EGFR).! EGFR! are! found! on!most! colorectal! cells!and!are!involved!in!signaling!pathways!that!are!deregulated!in!cancer!cells.!Inhibition! of! the! receptor! inhibits! growth,! causes! complement! activation!and!mediates!antibody!dependent!cellular!cytotoxicity.!(100)!!Its! effect! is! dependent! on! the! status! of! the! KRAS! protein! status! of! the!tumour.!Patients!with!KRAS!wild!type!tumours!have!been!shown!to!benefit!from! the! administration! of! the! targeted! antibodies! cetuximab! and!panitumumab.!!!
1.10.6!!!Bevacizumab!!Bevacizumab! is! a! recombinant! monoclonal! antibody! that! is! a! vascular!endothelial! growth! factor! inhibitor! (VEGF).! VEGF! is! a! signaling! protein!involved! in!angiogenesis.!Expression!of!VEGF!allows! tumours! to!grow!and!metastasise.!(100)!!
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1.11! Chemotherapy:Induced!Hepatotoxicity!!Despite! the! potential! advantages! of! neoJadjuvant! chemotherapy! in!colorectal! liver! metastases,! it! has! to! be! remembered! that! there! are! sideJeffects,!often!significant,! associated!with! its!use.!The! increasing!number!of!patients! receiving! chemotherapy! for! colorectal! liver!metastases! has! some!distinct! patterns! of! damage! being! recognised! and! associated! with! the!different! agents.! 5Jfluorouracil! has! been! found! to! be! associated! with!steatosis!(101),!while!irinotecan!has!been!implicated!in!the!development!of!steatohepatitis.! (102)! The! use! of! oxaliplatin! has! been! found! to! lead! to!development!of!a!vascular!condition!called!sinusoidal!obstruction!syndrome!(S.O.S.)!in!patients!receiving!that!particular!agent.!(103)!!It! is! important! that! a! liver! that! has! been! damaged! by! chemotherapy! is!recognised!early!as!the!future!remnant!liver!may!not!be!sufficient!to!provide!adequate! function! postJoperatively.! This! is! especially! important! when! a!major!resection!such!as!a!triJsectionectomy!is!planned.!!
!Figure!16:!Suggested!minimum!future!liver!remnant!for!patients!undergoing!surgery.!The!impact!of!chemotherapy!toxicity!is!not!well!defined!but!caution!is!advised.!(104)!!NonJalcoholic! fatty! liver! disease! (NAFLD)! is! a! spectrum! of! conditions!ranging! from! simple! steatosis! to! steatohepatitis,! fibrosis! and! eventually!cirrhosis.!A!summary!of!the!hepatotoxicity!associated!with!chemotherapy!is!shown!in!Table!6.!!!!!
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a more traditional length of therapy (1–8 cycles) [56]. They
showed that there was no difference in major pathological
response in those receiving the extra chemotherapy (57% vs.
55%, p = 0.74), but that the patients who received extended
cycles had a higher incidence of hepatotoxicity in the form
of SOS (26% vs. 42%, p = 0.017) and post-operative liver
insufficiency (4% vs. 11%, p = 0.035). This highlights the
importance of the type of chemotherapy rather than duration
and also that too much chemotherapy is bad for the liver.
Long-term data on the effect of chemotherapy induced
hepatotoxicity is limited. This is likely to be due to the
fact that patients receiving these chemotherapy agents have
advanced disease and only relatively small numbers of them
will be long-term survivors. The small numbers surviving
up to 10 years will make it difficult to accur tely assess
the impact of chemotoxicity in the long-term outcome of
patients.
Perhaps more importantly, the future role of the biolog-
ical agents such as the monoclonal antibodies currently in
clinical use needs to be explored in the context of hepatotoxic-
ity. The early studies with these biological agents do suggest
improved survival with the addition of these agents while
not causing noticeable hepatotoxicity. Indeed, an unpublished
review recently carried out by our group (Sathish et al.) [61]
has suggested that off-target toxicity such as hepatotoxicity
is not a significant problem across the whole class of bio-
logical agents [52]. With increasing evidence for the benefits
of these agents, this may be a way to reduce the burden of
hepatotoxicity for the patient.
Diagnosing hepatotoxicity pre-operatively remains a chal-
lenge. Currently, best practice is to monitor the patients liver
enzymes (ALT/AST) as a predictor of developing hepato-
toxicity. Unfortunately, despite this patients are still being
found to have chemotherapy damaged livers only at the
time of laparotomy. In order to detect toxicity earlier, dif-
ferent biomarkers must be found. The ideal biomarker is
easy to perform and exposes the patient to as little risk as
possible. Non-invasive tests are the ideal technique. Over-
man et al. have identified that 86% of patients treated with
oxaliplatin had CT evidence of splenic enlargement on post-
chemotherapy imaging [57]. This has been proposed as a
potential non-invasive biomarker of SOS, but only 22% of
patients developed SOS. Therefore, >60% of patients who
develop increased splenic size have not developed hepato-
toxicity meaning its use as a biomarker is not yet useful on
its own. The potential use of microRNA as a more sensi-
tive marker of hepatotoxicity than current liver enzymes is
also of some potential interest [58,59]. The gold-standard for
diagnosis of hepatotoxicity is liver biopsy. This is associated
with some considerable risk and therefore is not practica-
ble in every patient. The ideal situation would be that high
risk patients are identified through a combination of novel
biomarkers and this small sub-group could undergo biopsy
to allow for personalised treatment in the form of alteration
in the onocolgical or surgical management plan. Accurate
biomarkers for toxicity are essential if this approach is to
Fig. 8. The effect of chemotherapy-induced hepatoxicity on the required
future liver remnant.
be successful and this field is currently the focus of much
research and development.
Often the first time any significant hepatotoxicity is recog-
nised is at the time of surgery. This is particularly important
in patients undergoing large resections where the quality of
the future remnant liver may increase the risk of liver fail-
ure post-operatively. A tri-sectionectomy may be needed to
remove all the disease leaving the patient with a liver rem-
nant of around 20%. This will be sufficient to maintain basic
liver function after surgery assuming the liver is of good
quality and functioning normally. It is known that in livers
with impaired function such as cirrhosis, much larger rem-
nant livers of 40–50% are required prevent post-operative
liver failure (Fig. 8). It is not currently known where on this
spectrum patients with chemotherapy-induced hepatotoxic-
ity lie, but surgeons are concerned that a degree of impaired
function cannot be predicted. Prior knowledge of chemother-
apy induced liver damage could allow the surgeon to plan a
smaller resection, use ablation rather than resection, perform
a two-stage procedure or perform portal vein embolisation
to induce hypertrophy of the future remnant liver to allow
more functioning liver to reduce the risk of post-operative
liver failure [60].
Treatment of colorectal liver metastases has made
significant advances in the past 10 years. Combination
chemotherapy continues to increase the number of patients
suitable for surgical resection. Hepatotoxicity remains a small
but significant problem in this patient group. Future trials
need to address the problem from two fronts. Firstly, the
understanding of the underlying mechanisms of action and
hepatotoxicity will allow personalised therapy for individual
patients. KRAS testing and the use of bevacizumab to prevent
SOS are an example of this. Secondly, novel, sensitive and
specific biomarkers of hepatotoxicity need to be developed
to allow earlier detection of injury and alteration or cessation
of therapy in response to the detected damage.
8.  Conclusion
Liver resection for colorectal cancer metastases is becom-
ing more common and the number of available chemotherapy
agents is increasing. Although previously the domain of the
oncologist, it is becoming increasingly important that the sur-
geon is aware of the mechanism of action and hepatotoxicity
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Chemotherapy!Agent! Associated!Hepatotoxicity! Proposed!Mechanism!of!Hepatotoxicity! Incidence!of!Hepatotoxicity! Impact!of!Hepatotoxicity!5JFluorouracil!!Capecitabine! Steatosis! Impaired!βJoxidation!and!accumulation!of!fatty!acids.!




Cetuximab!!Panitumumab! No!recognised!hepatotoxicity! ! ! !Bevacizumab! No!recognised!hepatotoxicity! ! ! !! Table!6:!Summary!of!chemotherapyJinduced!hepatotoxicity!and!mechanisms!!
1.11.1!!!5:fluorouracil!and!steatosis!!Steatosis! is! defined! as! being! present! when! the! fat! content! of! the! liver! is!greater!than!5%!of! its!wet!weight.! Its!severity! is! traditionally!scored!using!the!Brunt!score!which!is!shown!below.!
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!Table!7:!The!Brunt!Score!for!grading!of!steatosis/steatohepatitis.!(110)!!Computed!tomography!has!shown!that!hepatic!fat!content!increases!by!30J47%!after!treatment!with!5JFU.!(111J113)!A!metaJanalysis!has!shown!that!the!presence!of!hepatic!steatosis!is!a!risk!factor!for!increased!periJoperative!morbidity!and!mortality! in!patients!having!major! (>3!segment)!resections.!(114)! However! several! other! studies! have! failed! to! show! any! significant!increase!in!complications.!(115,!116)!It!is!often!difficult!to!assess!the!impact!of!5JFU! in! isolation!as! it! is! rarely!used!as!a! single!agent! these!days.! It!has!also! been! shown! that! body!mass! index! (BMI)! has! a! significant! correlation!with! the! development! of! steatosis!when! receiving! chemotherapy.! Patients!with!a!BMI!>25!had!a!>20%!increased!risk!(p=0.02),!while!those!with!a!BMI!>30!were!at!increased!risk!of!severe!steatosis!(p=0.03).!Other!patient!factors!such! as! age,! gender! or! diabetes! did! not! affect! the! risk! of! developing!steatosis.!(117)!!Although! the! exact! mechanisms! of! chemotoxicity! are! still! poorly!understood,!there!are!some!widely!accepted!hypotheses.!As!well!as!breaking!5JFU! down! to! dihydrofluorouracil! (DHFU),! the! rateJlimiting! enzyme! DPD!also! produces! catabolites! such! as! fluoroJbetaJalanine! (FABL)! that! are!metabolised! in! hepatocytes.! It! has! been! shown! that! FABL! remains! in!hepatocytes! long! after! cessation! of! therapy! suggesting! that! the! pathways!involved! are! easily! saturated.! (111)! The! resulting! reduced! capacity! to!metabolise!drugs!and!fat!is!thought!to!lead!to!accumulation!of!intracellular!lipids.!5JFU!is!also!associated!with!collapse!of!the!mitochondrial!membrane!leading! to! impaired! oxidation! of! fatty! acids! and! increased! production! of!reactive!oxygen!species!(ROS)!mediated!by!cytochrome!p450!enzymes.!The!
Response ' 'Change'in'size'of'lesion'
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resulting!damage! from! the!ROS!and! impaired!betaJoxidation! leads! to! lipid!accumulation!and!steatosis.!(118)!!
1.11.2!!!Steatohepatitis!and!Irinotecan!!Steatohepatitis! is! a! more! worrying! condition.! It! has! been! shown! to! be!present!in!patients!with!Type!2!diabetes!mellitus,!obesity!and!the!metabolic!syndrome.! (119)! Vauthey! et! al! found! that! it! was! also! associated! with!receiving! irinotecan! therapy,! with! 20.2%! of! patients! receiving! therapy!developing!it!compared!to!4.4%!in!the!chemoJnaive!group.!(p=<0.001)!(107)!The!same!study!also!showed!that! there! is!a!significant! increase! in!surgical!morbidity!and!mortality!associated!with!developing!steatohepatitis!with!an!increased!90Jday!mortality!of!14.7%!vs!1.6%!(p=0.001).!However,!the!data!remains! inconclusive,! as! other! studies! have! failed! to! show! any! significant!difference.!(120)!Possible!confounding!factors!include!differing!rest!periods!after!chemotherapy!prior!to!surgery.!!The!precise!mechanism!of!irinotecan!hepatotoxicity!is!unclear!although!it!is!thought! to! involve! a! “2Jhit”! process.! The! first! “hit”! is! accumulation! of! fat!within! the! hepatocytes!with! oxidative! stress! caused! by! the! chemotherapy!providing! the! second! “hit”! resulting! in! the! development! of! the!hepatotoxicity.!!It!is!thought!that!mitochondrial!dysfunction!is!at!the!core!of!the! process.! (121)! Mitochondrial! function! and! that! of! the! mitochondrial!respiratory! chain! is! reliant! on! the! expression! of! several! polypeptides!encoded! by! the! mitochondrial! DNA! (mtDNA)! that! is! located! within! the!mitochondrial!matrix.! This! undergoes! continuous! replication! and! constant!levels!are!required!for!it!to!function.!If!the!level!of!mtDNA!drops!by!20J40%!below!basal!levels,!global!mitochondrial!dysfunction!can!develop.!(118)!The!dysfunction! causes! increased! production! of! reactive! oxygen! species! (ROS)!through! the! damaged! respiratory! chain,! increased! lipid! peroxidation! and!impairment! of! betaJoxidation.! This! can! trigger! release! of! proJapoptotic!(TNFJalpha)!and!proJfibrotic! (TGFJbeta)! cytokines!by!Kupffer! cells! leading!
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1.11.3!!!Sinusoidal!Obstruction!Syndrome!and!Oxaliplatin!!RubbiaJBrandt!et!al!showed!that!the!use!of!oxaliplatin!is!associated!with!the!development! of! sinusoidal! obstruction! syndrome.! (103)They! devised! a!scoring! system! of! increasing! hepatotoxicity! where! 0=absent,! 1=mild,!2=moderate!and!3=!severe.!The! features!of! sinusoidal!obstruction!develop!over! time! starting! with! sinusoidal! dilatation! progressing! to! hepatocyte!atrophy,!persinusoidal!fibrosis!and!later!nodular!regenerative!hyperplasia.!!Work! from! Vauthey! et! al! at! MD! Anderson! confirmed! that! there! was! a!significant! increase! in! the! incidence!of! sinusoidal!obstruction!syndrome! in!those! receiving! oxaliplatin! therapy! than! those! not! (18.9%! vs! 1.9%,!p=<0.001)!(107)However,!a!paper!from!Aloia!et!al!from!the!same!institution,!showed! that! although! there!were! changes! in! the! liver,! this!did!not! lead! to!increased! periJoperative! morbidity! or! mortality! although! there! was! an!increased!requirement!for!periJoperative!blood!transfusion!which!itself!is!a!risk!factor!for!complications.!!The! underlying! mechanisms! of! oxaliplatin! induced! sinusoidal! obstruction!syndrome!continue! to!be!poorly!understood.!Ultrastructural! abnormalities!in!the!liver!after!exposure!to!oxaliplatin!has!shown!that!there!is!an!increased!rate!of!endothelial!cell!apoptosis!leading!to!leaky!vessel!walls.!This!leads!to!extravasation! of! erythrocytes! into! Disse’s! space! and! deposition! of!extracellular!matrix! components! including! collagen! fibres! leading! to! periJsinusoidal! fibrosis.! The! dilatation! of! Disse’s! space! and! blebs! from! the!endothelial! cells! bulging! into! the! sinusoidal! lumen! lead! to! the! obstructive!syndrome.!(125)!!
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!Figure!18:!IntraJoperative!view!of!the!characteristic!“blue!liver”!of!oxaliplatin!induced!sinusoidal!obstruction!syndrome!and!histology!of!the!same.!(kindly!provided!by!Professor!Graeme!Poston,!Liverpool,!UK)!!!!It!is!thought!that!increased!generation!of!reactive!oxygen!species!(ROS)!and!glutathione!depletion!from!sinusoidal!endothelial!cells!causes!the!increased!apoptosis! in! these! cells! allowing! the! damage! to! occur.! UpJregulation! and!increased! activity! of! matrix! metallopeptidase! 9! (MMPJ9)! has! also! been!implicated!in!the!process.!(105)!!
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!Figure!19:!Possible!mechanism!of!the!development!of!Sinusoidal!Obstruction!Syndrome.!(105)!!Recent!work!has!shown! that! there! is!upJregulation!of! several!genes! in! the!sinusoidal! obstruction! syndrome.! These! included! genes! involved! in!regulating!angiogenesis,! cellular! adhesion!and! inflammation.! (126)!MMPJ9!in! particular! is! associated! with! pathological! processes! including! cancer!invasion,! metastasis! and! angiogenesis.! There! have! been! efforts! to! direct!novel! therapies! into! targeting! this!pathway! in! the! treatment!of! cancer!but!work! is! at! an! early! stage.! (127)! Of! interest,! it! has! been! shown! that! in!patients! receiving! the! VEGF! inhibitor,! bevacizumab,! there! has! been! a!reduction!in!the!incidence!of!SOS.!Understanding!the!mechanisms!involved!in!this!process!could!help!develop!novel!ways!of!preventing!it.!(125)!!
1.11.4!!!Long:term!implications!of!hepatotoxicity!!Little! is! known! about! the! natural! history! of! the! conditions! caused! by!chemotherapy,!mainly!because!of!small!numbers!and!the!deaths!of!patients!from! their! disease! before! longJterm! followJup! is! possible.! There! has! been!some!recent!data!that!in!addition!to!the!periJoperative!complications,!there!is! a! longerJterm! oncological! impact! in! patients! who! develop! these!conditions.! Tamandl! et! al,! demonstrated! shorter! disease! free! survival!(p=0.05)! and! overall! survival! (p=<0.001)! in! patients! who! had! developed!sinusoidal!obstruction!syndrome!as!a!consequence!of!oxaliplatin.!(109)!!
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oxidation of fatty acids and lead to subsequent 
accumulation of ROS within hepatocytes.12 Fluorouracil is 
also associated with the generation of ROS by microsomal 
cytochrome P450 enzymes. Furthermore, fl uorouracil is 
metabolised to catabolites such as fl uoro-β-alanine, which 
might decrease the capacity of hepatocytes to metabolise 
substances such as drugs and lipids.13
Steatohepatitis and irinotecan
In the largest study of chemotherapy-associated liver 
injury,14 irinotecan was associated with the development of 
steatohepatitis in four of 33 (12%) of patients with BMI 
less than 25 kg/m² and 15 of 61 (25%) with BMI of 25 kg/m² 
or more. The association between steatohepatitis and 
irinotecan has been confi rmed in other studies.11,15 As with 
fl uorouracil, a molecular basis for the association between 
irinotecan and steatohepatitis is not well-defi ned. Results 
from studies of other drugs that cause steatohepatitis, such 
as amiodarone and tamoxifen, show that agents with 
lipophilic moieties cross the mitochondrial membrane, 
reach high intramitochondrial concentrations, and inhibit 
mitochondrial oxidation and electron transfer along the 
respiratory chain, resulting in production of ROS.16 Notably, 
irinotecan is a precursor of the lipophilic metabolite SN-38 
and is inactivated by means of oxidative metabolism by 
microsomal cytochrome P450 enzymes.17
Hepatic sinusoidal injury
Sinusoidal injury ranges from sinusoidal dilation to 
hepatic sinusoidal obstruction syndrome, also termed 
veno-occlusive disease, which can progress to regenerative 
nodular hyperplasia.18 Injury to the sinusoidal endothelial 
cells lining the sinusoids, the initial event, leads to 
subintimal thickening and extravasation of erythrocytes 
into the subendothelial space of Disse (perisinusoidal 
space). Sinusoidal endothelial cells and erythrocytes 
embolise in sinusoids and block venous outfl ow, resulting 
in hepatic congestion and sinusoidal dilatation. At later 
stages, a fi brotic reaction in the sinusoids can lead to 
obliteration of central venules, leading to hepatic 
sinusoidal obstruction syndrome.
Hepatic sinusoidal obstruction syndrome was originally 
described in Jamaica, in drinkers of bush tea containing 
pyrrolizidine alkaloids. Monocrotaline is a pyrrolizidine 
alkaloid used to induce hepatic sinusoidal obstruction 
syndrome in animals (fi gure 4).19 Monocrotaline depletes 
glutathione and increases production of ROS, leading to 
oxidative stress. Additionally, monocrotaline leads to 
depolymerisation of actin in sinusoidal endothelial cells, 
which might upregulate matrix metalloproteinases 
(MMPs) MMP-9 and MMP-2. The increase in MMP-9 
activity causes detachment of endothelial cells from the 
space of Disse and embolisation into the sinusoids. 
Furthermore, monocrotaline decreases concentration of 
nitric oxide in hepatic veins, which upregulates MMP-9 
activity and contributes to the development of hepatic 
sinusoidal obstruction syndrome in mouse models.20
In human beings, hepatic sinusoidal obstruction syn-
drome is most commonly associated with high-dose 
chemo therapy and stem-cell transplantation and its 
symptoms include hepatomegaly, ascites, and 
jaundice. Patients with veno-occlusive disease have high 
concentrations of endothelin-1, vascular endothelial 
growth factor (VEGF), and plasminogen activator-1 
(fi gure 4).18,21,22 Endothelin-1 mediates sinusoidal 
constriction, and aggravates the impedance to venous 
fl ow in HSOS. In animal models (rodents), VEGF 
probably leads to hyperdynamic splanchnic circulation 
and portal hypertension, and plasminogen activator-1 is a 
cause in the development of hepatic vein thrombosis.21,22 
Thus, angiogenic and vasoactive factors might have an 
important role in the pathogenesis of sinusoidal injury.
Sinusoidal injury and oxaliplatin
In a study by Rubbia-Brandt and colleagues,23 34 of 
43 patients (78%) treated with oxaliplatin showed sinusoidal 
dilatation; graded as mild, moderate, or severe, according 
CV
Figure 3: Steatohepatitis 
Moderate steatosis (40–50% of hepatocytes), hepatocyte-ballooning degeneration 
(black arrow), lobular infl ammation (green arrow), and portal infl ammation (green 
arrowhead). Kleiner score for non-alcoholic fatty liver disease is 6. CV=central vein. 













Figure 4: Possible mechanisms of sinusoidal injury
Monocrotaline induces hepatic sinusoidal obstruction syndrome (HSOS) by 
upregulating matrix metalloproteinases (MMPs), decreasing concentrations of 
nitric oxide (NO), and glutathione. Plasminogen activator-1 (PAI-1), 
endothelin-1, and vascular endothelial growth factor (VEGF) are overexpressed. 
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1.12! Outcomes!in!Colorectal!Liver!Metastases!!The! advances! in! chemotherapy! and! surgical! technique! have! had! a! major!impact! on! the! survival! in! colorectal! liver! metastases.! In! a! large,!retrospective!review!of!over!110,000!patients!with!colorectal!cancer!in!the!United! Kingdom! between! 1998J2004,! there!were! 3116! patients! identified!who! underwent! hepatectomy.! The! overall! 5Jyear! survival! rate! following!liver!resection!was!45.9%!(95%!C.I.!44.1J47.7%),!which!was!actually!better!than!the!5Jyear!survival!rate!for!those!with!Stage!III!disease!at!42.2%!(95%!C.I.! 41.7J42.7%).! The! 5Jyear! survival! for! nonJresected! Stage! IV! was! 9.0%!(95%!C.I.!8.4J9.6%).(128)At!present!there!is!no!staging!system!that!reflects!the!fact!that!Stage!IV!patients!who!are!resected!have!as!good!an!outcome!as!those!with!earlier!Stage!III!disease.!(38)!!There! is! a! need! for! novel! biomarkers! of! chemotherapyJinduced!hepatotoxicity.! Current! practice! is! to! monitor! patients! receiving!chemotherapy! with! standard! liver! function! tests! including! bilirubin,!ALT/AST! and! alkaline! phosphatase.! Although! the! current! gold! standard,!these!tests!are!often!not!reliable!enough!to!detect!hepatotoxicity,!as!despite!normal! serum! results! during! chemotherapy,! it! is! not! until! the! time! of!surgery!when!the!damage!is!detected,!by!which!time!it!can!have!a!significant!effect! on! the! operative! strategy.! The! need! for!more! sensitive! and! specific!biomarkers!is!recognised!in!a!number!of!conditions!and!the!role!of!serumJbased!microRNAs!have!been!proposed!as!a!possible!solution.!!














1.14.1!!!Role!of!miR:122!in!liver!development!!It!has!been!shown!that!there!is!a!significant!spike!in!levels!and!upJregulation!of!miRJ122!during!embryonic!development!of!the!liver.!This!has!suggested!a!role! for! miRJ122! in! the! regulation! of! hepatocyte! differentiation,! liver!development!and!maintaining!the!adult!phenotype.!(143)!In!a!study!in!mice,!Xu!et!al!identified!four!liver!specific!transcription!factors!namely!hepatocyte!nuclear! factor! (HNF)J1α,! 3β,! 4α! and! CCAAT/enhancerJbinding! protein! α!(C/EBPJα),! that! activated! miRJ122! expression.! This! caused! a! down!regulation!of!genes!involved!in!the!differentiation!of!hepatocytes.!(144)!!
1.14.2!!!Role!of!miR:122!in!lipid!metabolism!!MiRJ122!was!the!first!miRNA!to!be!identified!as!having!a!role!in!regulating!lipid!metabolism.!(142)!Because!it!is!plentiful!and!specific!to!the!liver!it!has!been!hypothesised!that!it!has!a!role!in!cholesterol!and!fatty!acid!metabolism.!There!have!been!a!number!of!studies!using!mouse!models!where!antisense!strategies!have!been!used!to!sequester!miRJ122.!The!mice!have!been!found!to! decrease! levels! of! cholesterol,! low! density! lipoprotein! (LDL)! and! high!density!lipoprotein!(HDL)!in!both!the!liver!and!bloodstream.!There!was!also!decreased!fat!accumulation!in!the!liver.!(145J148)!In!mice!fed!with!high!fat!diets,! miRJ122! silencing! has! led! to! decreased! hepatic! steatosis,! reduced!cholesterol! synthesis! rates!and! increased!hepatic! fatty!acid!oxidation.!This!has! led! to! interest! in! a! potential! role! for! miRJ122! in! the! treatment! of!dylipidaemias.!!
Chapter(1(
! 43!
1.14.3!!!miR:122!and!Hepatitis!C!Virus!!Hepatitis!C!(HCV)!is!a!positive!sense!RNAJvirus!affecting!around!180!million!people! worldwide.! It! is! associated! with! chronic! liver! disease! and! the!development! of! fulminant! hepatic! failure.! Jopling! et! al! were! the! first! to!identify!the!important!role!of!miRJ122!in!the!replication!and!development!of!HCV.! They! found! that! there! were! two!miRJ122! binding! sites! on! the! viral!mRNA.!One!was!found!to!be!in!the!5’JnonJcoding!region!(NCR)!and!the!other!in!the!3’JNCR.!It!was!shown!that!miRJ122!needed!to!bind!to!the!viral!mRNA!for!replication!to!occur.!Treatment!to!sequester!and!inhibit!miRJ122!led!to!a!significant!decrease!in!replicating!viral!mRNA.!(149)!Since!then!a!number!of!other!studies!have!been!performed!with!similar!outcomes!adding!weight!to!the! hypothesis! that!miRJ122! is! essential! for! HCV! development.! (150J153)!There!is!also!evidence!that!the!miRJ122/RISC!complex!actually!stabilises!the!HCV! viral! RNA! conferring! protection! against! damage! to! it.! (154)! There! is!currently!a!lot!of!interest!in!the!potential!use!for!miRJ122!based!therapies!in!the!treatment!of!HCV.!!
1.14.4!!!miR:122!and!Hepatitis!B!Virus!!Hepatitis!B!Virus!(HBV)!is!a!DNA!virus!affecting!around!350!million!people!worldwide.! It! causes!acute!and! chronic! infection! that! can! lead! to! cirrhosis!and!hepatocellular!carcinoma!(HCC).!The!role!of!miRJ122!and!HBV!has!been!less! extensively! investigated! than! its! sister! virus,! HCV.! Despite! this,! it! has!been!shown!that!miRJ122!also!plays!an!important!role! in!the!regulation!of!HBV.!In!animal!models!it!has!been!shown!that!transfection!of!miRJ122!into!a!cell!inhibits!HBV!replication!while!antisense!inhibition!of!miRJ122!causes!an!increase! in! HBV! replication.! This! pattern! is! the! complete! opposite! in!contrast! to! its! role! in!HCV.! (155)Further!studies!have!confirmed!that!miRJ122! strongly! inhibits! HBV! expression! and! replication! as! well! as! acting! to!suppress! cell! proliferation! and! malignant! transformation! of! hepatocytes.!(156J158)!These!findings!raised!the!question!of!why!HBV!existed!in!such!a!
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place!where!miRJ122,!a!potent!inhibitor,!is!so!highly!expressed.!Wang!et!al!attempted!to!answer!this!and!found!that!in!patients!with!HBV,!intracellular!expression!of!miRJ122!in!hepatocytes!was!significantly!reduced.!(159)!This!has!led!to!exciting!hypotheses!that!the!HBV!virus!interacts!with!its!host!via!unknown! pathways! to! cause! downJregulation! of! miRJ122! to! allow! its!survival.!!
1.14.5!!!miR:122!and!Hepatocellular!Carcinoma!!There! is! increasing! evidence! and! interest! in! the! role! of! miRJ122! in!carcinogenesis,! particularly! hepatocellular! carcinoma! (HCC).! MiRJ122!expression!has!been!shown!to!be!reduced!in!these!tumours,!and!the!degree!of!downJregulation!has!been!shown!to!be!associated!with!prognosis.!Lower!expression! of! miRJ122! is! associated!with! poor! prognosis! and!metastases.!(160J163)! MiRJ122! has! been! shown! to! be! involved! in! cell! proliferation,!apoptosis,!migration,!invasion!and!tumour!formation.!Inhibition!of!miRJ122!increases! the! rate!of! these! functions!while! restoring! the!miRJ122!reverses!the! effect.! OverJexpression! of! miRJ122! has! been! shown! to! sensitise! the!tumour!to!the!effects!of!chemotherapy.!(164J166)!There!is!intense!interest!in!the!use!of!miRJ122!in!the!treatment!of!HCC,!particularly!as!currently!it!is!associated!with!such!a!poor!prognosis.!!
1.15! miR:122!as!a!biomarker!!Novel!biomarkers!are!essential!to!facilitate!preJclinical!and!clinical!research!and! practice.! In! the! field! of! drugJinduced! liver! injury! (DILI)! there! is! an!urgent! need! for! new,!more! sensitive! and! specific! biomarkers.! The! official!Federal! Drug! Administration! (FDA)! definition! of! a! biomarker! is! “a!characteristic!that!is!objectively!measured!and!evaluated!as!an!indicator!of!normal! biologic! processes,! pathological! processes! or! pharmacological!responses! to! a! therapeutic! intervention”.! In! practice! a! biomarker!must! be!
Chapter(1(
! 45!
readily!available! in!as!nonJinvasive!manner!as!possible.! It!must!be!specific!and!sensitive!and!the!test!must!be!easily!reproducible.!!Sensitivity!measures!the! proportion! of! actual! positives! which! are! correctly! identified! as! such!(true!positive!rate).!Specificity!measures!the!proportion!of!negatives!which!are!correctly!identified!as!such!(true!negative!rate).!It!has!been!shown!that!miRNA!is!highly!stable! in!plasma.!Coupled!with! its!relative!abundance!and!tissue!specificity,!it!has!been!proposed!as!a!potential!biomarker!in!a!number!of! situations.! (167)! With! its! high! specificity! for! liver,! there! is! increasing!interest!in!the!potential!use!of!miRJ122!as!a!biomarker!for!DILI.!Current! biomarkers! of! hepatotoxicity! are! bilirubin,! alkaline! phosphatase!(ALP),! alanine! aminotransferase! (ALT)! and! aspartate! aminotransferase!(AST)! known,! incorrectly! as! liver! function! tests! (LFTs).! In! particular! the!enzymes!ALT! and!AST! are! used! as!markers! of! hepatocyte! damage.! Severe!hepatotoxicity!is!defined!as!levels!>3!times!the!upper!limit!of!normal!(ULN).!During! the! necrosis! of! hepatocytes! the! enzymes! leak! into! the! systemic!circulation.! Serum! ALT! level! has! been! shown! to! be! correlated! with! the!amount! of! hepatocyte! damage.! (168)! The! drawback!with! ALT! and! AST! is!that!they!are!not!solely!found!in!liver.!Two!isoforms!of!ALT!exist,!ALT!1!and!ALT2.! These! are! also! expressed! in! lower! but! significant! levels! in! other!tissues!such!as!muscle,!bowel!and!myocardium.!Levels!can!be!raised!above!normal! in! conditions! such! as! myositis! and! myocardial! infarction.! (168)In!fact! ALT! and! AST! have! previously! been! used! as! “cardiac! enzymes”! as!biomarkers!of!acute!myocardial!infarction!prior!to!the!discovery!of!cardiacJspecific!troponins.!Wang!et!al!produced!a!landmark!paper!on!the!use!of!miRJ122!in!DILI.!Using!mice!they!showed!that!after!receiving!a!toxic!dose!of!paracetamol,!miRJ122!levels! increased! earlier! than! ALT! and! at! lower! concentrations! of!paracetamol! suggesting! that! it! is!more!sensitive! than! the!current!markers.!(169)Yamaura! et! al! published! similar! findings! in! rats! confirming! its!potential!as!a!biomarker!across!species.!(170)!Following!on!from!this!there!have!been!studies!in!a!human!population.!In!our!own!group,!StarkeyJLewis!et! al! confirmed! its! potential! as! a! biomarker! in! patients! with! acute! liver!failure!following!paracetamol!overdose.!Their!findings!were!similar!to!those!
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of!Wang!et!al,!showing!that!there!is!good!correlation!between!miRJ122!and!ALT,!but!that!the!rise!in!miRJ122!occurred!at!an!earlier!time!point.!(171)!The! role! of! miRJ122! as! a! biomarker! in! a! variety! of! conditions! has! been!explored.!Different!aetiologies!of!hepatotoxicity!in!which!miRJ122!has!been!suggested!as!a!potential!biomarker!include!HCV!(172),!HBV!(173J175),!HCC!(173;! 174),! acute! liver! transplant! rejection! (176)! and! alcoholic! liver!cirrhosis! (177)! Yang! et! al! explored! the! use! of! biofluids! other! than! blood.!Having! given! rats! toxic! doses! of! paracetamol! and! other! drugs,! they! were!able!to!measure!raised!levels!of!miRJ122!in!urine.!(178)!There!is!currently!major!interest!in!the!potential!uses!for!miRJ122!as!a!biomarker!in!a!range!of!liver!injuries.!
!




• MiRJ122! will! be! more! sensitive! than! serum! transaminases! in! liver!disease!and!injury.!










2.1! Introduction!!ChemotherapyJinduced! hepatotoxicity! is! a! common! problem! for! patients!undergoing!treatment!for!colorectal!liver!metastases!affecting!up!to!78%!of!all! patients.! (179)! Patients! receiving! chemotherapy! are! monitored! both!clinically!and!biochemically!during!their!treatment!to!detect!sideJeffects!that!may! develop.! Unfortunately,! despite! this! monitoring,! patients! continue! to!develop!significant!liver!injury!that!is!not!detected!until!laparotomy!when!it!may!impact!on!outcome.!(105;!107J109)!!!!!To! date,! only! a! relatively! small! number! of! tests! are! used! to! assess! liver!integrity.!These!primarily!consist!of!serum!total!bilirubin!(marker!of!hepatic!function)! and! the! determination! of! the! serum! activity! of! the! enzymes!alkaline! phosphatase! (marker! of! biliary! injury)! and! aspartate!aminotransferase! (AST)! and! alanine! aminotransferase! (ALT),! markers! of!hepatocellular!injury.!!Serum!ALT!activity!has!become!the!primary!screening!tool!for!the!detection!of! liver! injury! and! disease.! However,! changes! in! ALT! activity! occur! in! a!number!of! liver!disease!etiologies!such!as!drugJinduced! liver! injury!(DILI),!viral!hepatitis,!fatty!liver!disease!and!liver!cancer.!!Expression!of!ALT!is!not!specific!to!the!liver!and!increased!serum!levels!can!also!be!detected!in!other!conditions! such! as! myocardial! damage,! muscle! toxicity,! myositis! and!extreme!exercise.!Furthermore,!ALT!activity!does!not!always!correlate!with!histopathological! damage! that! results! in! a! significant! impediment! to! the!interpretation! of! its! results.! (168)! Recently,! the! use! of! the! hepatocyteJspecific! microRNAJ122! (miRJ122)! has! been! proposed! as! a! superior!biomarker!for!hepatic!injury!and!disease.!Proposed! potential! advantages! of! miRJ122! over! conventional! tests! are!increased! organ! specificity,! presence! in! a! nonJinvasive! biofluid! (blood,!urine)! and! low! baseline! variation! in! the! healthy! population.! Furthermore,!the! development! and! validation! of! assay! methodologies! that! are! robust,!translational! and! can! be! used! in! many! laboratories! is! critical! to! the!
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development! and! qualification! of! novel! experimental! biomarkers! such! as!miRJ122.!Therefore,! the!objective!of! this! investigation!was! to!quantify! the!circulating!level!of!miRJ122!in!a!healthy!population!and!to!define!a!normal!reference! range,! degree! of! variation! and! associate! potential! impact! of! age!and! sex! that! can!be!used! to! assess! changes! found! in!patients!with!hepatic!injury!and!disease.!!




StarkeyJLewis!et!al!have!previously!described!the!method!used!for!analysis!of! the!miRJ122!used!by!our!group! in!detail! in!2011.!(171)! In!brief,!miRNA!was!extracted!using!an!miRNeasy!kit!(Qiagen,!Venlo,!Netherlands)!following!the! manufacturer’s! instructions! with! a! few! minor! modifications.! Briefly,!40uL! of! biofluid! was! made! up! to! 200μL! with! nuclease! free! water! then!combined!with!700μL!of!QIAzol.!The!sample!was!mixed!and!left!to!incubate!for! 10! minutes! at! room! temperature! before! the! addition! of! 140μL! of!molecular!grade!chloroform.!At!this!point!5uL!of!C.linJ4!was!spiked!in.!The!samples!were! vortexed! for! 15! seconds! and! centrifuged! at! 12,000g! for! 15!minutes! at! 4°C.! Equal! volumes! (350μL)! of! the! aqueous! upper! phase! and!70%! ethanol! were! mixed! in! a! fresh! microtube! before! adding! the! total!volume! to! an!miRNeasy!minispin! column.! The! column!was! centrifuged! at!8,000g! for! 15! seconds! at! room! temperature.! The! flowthrough,! containing!the! small! RNA! fraction! (including! the! miRNA)! was! mixed! with! 450μL! of!100%! ethanol.! The! elute! was! then! purified! using! an! RNeasy!MinElute! kit!(Qiagen,!Venlo,!Netherlands).!!
2.2.2! miRNA!purification!!The!small!RNA!elute!was!applied!to!the!RNeasy!MinElute!column!700μL!at!a!time! and! centrifuged! at! 8,000g! for! 15! seconds! at! room! temperature.! The!miRNA! immobilised! in! the!columns!was! then!washed!with!various!buffers!before! a! final! 80%! ethanol! wash.! The! column! was! then! airJdried! by!centrifuging!with!the!lid!open.!The!miRNA!fraction!was!then!eluted!in!14μL!of!nuclease!free!water.!!




2.2.4! Quantitative!Polymerase!Chain!Reaction!Analysis!!1.33μL!of! cDNA!was!used! in! the!PCR!mixture!with! specific! stemJloop!PCR!primers! (Applied! Biosystems,! Foster! City,! CA)! in! a! total! volume! of! 20μL.!Levels!of!miRNA!were!measured!by!the!fluorescent!signal!from!the!Taqman!probes! on! an! ABI! Prism! 7000! (Applied! Biosystems).! All! samples! were!assayed! in! duplicate.! Results! were! expressed! as! the! cycle! threshold! (Ct),!defined! as! the! PCR! cycle! number! at! which! the! signal! rises! above! the!baseline.!When! performed,! normalisation!was! done! using! the! ΔCt!method!(Ct!target!RNAJ!Ct!control!RNA).!!
2.2.5! Relative!Quantification!using!a!Standard!Curve!!A!standard!curve!was!defined!using!a!synthetic!oligonucleotide!of!miRJ122!(IDT,!Leuven,!Belgium).!A!serial!dilution!from!a!starting!concentration!of!109!copies! per! PCR! well! was! made! down! to! 102! copies! per! well.! This! was!assayed! in!duplicate!with! three! replicates.!Applying!PCR!CT! values! to! this!standard!curve!made!relative!quantification.!!
2.2.6! ALT!Levels!Determination!!Serum!ALT! levels!were!determined! in! the!hospital! laboratory!of! the!Royal!Liverpool!University!Hospital!after!sampling.!!
2.2.7! Statistical!Analysis!!Descriptive! statistical! analysis! was! performed! on! the! patients! including!medians!and!range.!To!determine!statistical!significance,!comparisons!were!made!using!the!Students!tJtest!(for!parametric!data)!and!the!MannJWhitney!U! test! (for! nonJparametric! data.! Correlative! analysis! was! made! using!Pearson’s! test! and! variation! was! assessed! using! coJefficient! of! variation!which!is!a!ratio!of!the!standard!deviation!to!the!mean,!showing!the!extent!of!
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variability! in!relation! to! the!mean!of! the!population.!All! statistical!analysis!was! carried! out! using! GraphPad! Prism! software! (GraphPad! Software,! La!Jolla,!CA).!Statistical!significance!was!set!at!p=0.05.!Normal!reference!ranges!were!calculated!as!the!95%!prediction!interval!of!the!population.!!
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Reference!ranges!for!mirJ122!copy!number/uL!of!serum!as!well!as!ΔCt!miRJ122/U6snRNA! and! ΔCt! miRJ122/letJ7d! were! calculated.! The! upper! and!lower!limits!of!the!reference!range!were!defined!95%!prediction!interval!of!the!population.!(Table!8J9).!!!Biomarker! Mean! Median! Lower! reference!range! Upper! reference!range!ALT! 29.78! 30.00! 13.50! 48.50!miRJ122!(CT)! 27.79! 27.52! 25.51! 30.23!miRJ122!(CT/U6)1! 42.10! 51.42! 4.81! 259.82!miRJ122! (CT/letJ7d)2! 4.08! 3.84! 0.37! 11.90!MiRJ122!(copynumber)1! 10301! 12088! 2489.91! 38948.67!! Table!8:!General!Reference!Ranges!for!miRJ122!expressed!in!a!number!of!different!ways.!!Biomarker! Gender! Mean! Median! Lower!reference!range!
Upper!reference!range!ALT! Female!Male! 29.59!30.04! 28.00!30.00! 16.40!12.50! 49.20!48.50!miRJ122!(CT)! Female!Male! 27.79!27.80! 27.75!27.43! 25.34!25.82! 30.03!30.79!miRJ122!(CT/U6)1! Female!Male! 40.85!43.38! 46.06!57.97! 5.10!3.32! 262.43!225.88!miRJ122!(CT/letJ7d)2! Female!Male! 3.88!4.32! 3.42!4.24! 0.40!0.28! 13.99!11.90!MiRJ122!(copynumber)1! Female!Male! 10404!10310! 10614!12708! 2807.36!1790.05! 43044.94!32532.67!! Table!9:!Reference!ranges!by!gender!
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!Analysis! of! the! intraJpatient! variation! over! 3! days! showed! little! variation!(Figure!32)!with!the!mean!standard!deviation!and!95%!confidence!interval!being!shown!in!Table!10.!!
!!Figure!32:!3!day!individual!variation!of!miRJ122!by!Ct!value!in!50!healthy!volunteers.!There!was!no!significant!difference!over!this!time!period.!(p=0.66).!!!!!Biomarker! N! Mean! Standard!deviation! 95%! Confidence!interval!ALT!(U/L)!!!!!!!!!!!!!!!!!!!!!!!!!!! 50!x!3! 1.54! (1.44,!1.64)!MIRJ122!(CT)! 50!x!3! 1.019! (1.016,!1.022)!MIRJ122(DCT/U6)! 41!x!3! 2.66! (2.29,!3.09)!MIRJ122(DCT/letJ7d)! 50!x!3! 2.13! (1.86,!2.44)!MIRJ122(COPY!number/UL)! 50!x!3! 1.33! (1.27,!1.40)!! Table!10:!Variation!of!miRJ122!over!3!days!in!50!healthy!volunteers.!!
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on! intra! and! interJindividual! variation! of! circulating! miRJ122! in! healthy!individuals.!!!The!data!obtained! from!this! investigation!show!that!miRJ122! is!detectable!in!the!serum!of!healthy!patients!and!that! it!has!a!very!low!degree!of! interJindividual! variation.! Furthermore,! we! have! also! shown! that! there!was! no!significant! variation! when! age! or! gender! was! taken! into! consideration.!These! findings!were! also! reproduced! for! both! of! the! endogenous! controls!commonly!used!for!normalization!of!circulating!miRJ122.!!!The!study!also!showed!that!there!is!little!temporal!variation,!both!in!terms!of! a! circadian! variation! over! 24! hours! and! over! 3! consecutive! days.! Of!interest! is! the! difference! between! intraJ! and! interJpatient! variation.! The!CV%!of!the!population!is!excellent!at!around!5%,!but!the!24!hour!sampling!revealed!that!the!intraJpatient!variation!is!even!less,!at!under!2%.!This!could!be! beneficial! if! using! serum!miRJ122! as! a! longJterm!marker! in! the! same!patient!to!assess!response!to!therapy!of!development!of!hepatotoxicity,!as!is!done!in!Chapter!4.!!For!the!assay!and!quantification!of!circulating!RNAs!as!biomarkers,!there!is!a! need! for! robust! normalizing! controls! to! ensure! the! validity! of! the! data.!C.linJ4!has!previously!been! reported!and!utilized!as!an!exogenous!control.!Therefore,!within!this!current!investigation!C.linJ4!was!utilised!to!assess!the!quality! of! RNA! extraction,! reverse! transcription! and! PCR.! The! excellent!coefficient! of! variation! (3.91%)! confirmed! that! a! consistent! extraction,!purification! and! amplification! of! the! RNA! had! occurred.! It! has! been!suggested! that! an! exogenously! spikedJin! RNA! could! be! used! for!normalization.! We! have! shown! that! synthetic! miRNA! degrades! over! time!and! as! such! it! has! limitations! in! its! use.! The! use! of! endogenous! controls!allows!correction!for!any!differences!in!the!quality!of!the!starting!material.!U6snRNA!and!letJ7d!have!been!reported!as!endogenous!control!for!miRJ122!normalization.!Within!this!study!both!the!U6snRNA!and!letJ7d!also!showed!a!low!coefficient!of!variation.!Within!the!published!literature,!the!use!of!the!
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endogenous! controls,! such! as! U6snRNA! and! letJ7d,! as! a! normaliser! is! the!subject!of!much!debate.!(180)!Several!different!small!RNA’s!and!microRNA’s!have! been! suggested! as! the! ideal! normaliser.! In! reality,! it! has! become!apparent! that! there! is! no! ideal! normaliser! and! this! subject! is! a! rapidly!evolving! field! and! one! that! requires! further! investigation.! Despite! both!U6snRNA! and! letJ7d! controls! showing! a! low! degree! of! variation,! when!applied! as! normalisers! to! the! raw! miRJ122! data,! they! gave! noticeably!different!results.!The!normalised!miRJ122!range!by!U6snRNA!in!particular!was! significantly! larger! than!when!normalised!by! letJ7d.!The!difference! in!range! could! be! attributed! to! the! difference! in! Ct! values! between! the!normalizing! controls! and! the! target! (miRJ122).! The! letJ7d! has! a! mean! Ct!close!to!that!of!miRJ122,!leading!to!a!narrow!range,!while!the!U6snRNA!has!a!mean!Ct!value!higher! than!miRJ122!which!resulted! in!a!higher!observed!ΔCt!value.!However,!when!normalized!values!were!correlated!at!the!level!of!the!individual!subject,!they!showed!a!strong!and!significant!relationship!and!therefore! either! would! be! appropriate! to! use.! In! reality,! it! has! been!suggested!that!it!would!be!appropriate!to!use!a!control!with!a!Ct!value!closer!to!the!miRJ122,!in!this!case!letJ7d.!(180)!!!The! use! of! %! coefficient! of! variation! to! assess! the! variability! of! these!molecules!has!both!advantages!and!disadvantages.!It!has!the!advantage!over!standard!deviation!in!that!it!is!better!when!comparing!data!sets!with!widely!different!means,!as!seen! in!this!experiment.!However,! its!disadvantages! lie!in!the!fact!that!it!can!be!sensitive!to!small!changes!in!the!mean!and!cannot!be!used!to!create!confidence!intervals.!In!this!experiment,!depending!on!the!method!used! to! express! the!data! (Ct,! normalised! to! control! or! copies/uL),!there!is!a!wide!difference!in!the!%CV.!Measuring!raw!Ct!may!not!be!ideal!as!it! is!a! logJscale!and!small!variation!can!actually!represent!large!differences!as! seen! by! the!%CV! of! the! normalised! results.! In! reality,! there! remains! a!need! for! a! standardised! method! of! expressing! data! that! is! universally!accepted.!!
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3.1! Introduction!!The! potential! use! of! microRNAJ122! as! a! circulating! serum! biomarker! for!liver! injury!and!toxicity! is!currently!the!focus!of!much!investigation.! Initial!work! mainly! focused! on! drug! toxicity! in! animal! models! with! Wang! et! al!showing! in! 2009! that! mice! receiving! a! toxic! dose! of! paracetamol! had!significantly!raised!levels!of!miRJ122!and!that!these!levels!rose!before!ALT.!(169)! The! publication! of! a! similar! study! in! rats! suggested! that! this! effect!might!be!seen!across!species.!(170)!Recently,!work!performed!in!the!human!population! following! acute! paracetamol! overdose! (171)! has! shown! that!serum!miRJ122!levels!are!significantly!raised!as!well!as!in!a!range!of!other!conditions! including! hepatitis! B! and! C! infection! (172;! 173;! 175)! ,!hepatocellular!carcinoma!(174)!and!acute!transplant!rejection.!(176)!!The! major! limitation! of! these! studies! is! the! lack! of! multiple,! different!aetiologies!of!underlying!disease! to! allow!comparison.!As!discussed! in! the!previous! chapter,! a! cycle! threshold! value! (Ct)! cannot! be! used! to! compare!between! different! experiments! as! the! number! is! set! specifically! by! the!instrument!used!and!makes!no!allowance! for!differing!methodology.!Thus,!although!all!the!conditions!studied!may!lead!to!raised!levels!of!miRJ122,!the!relative! differences! between! this! variety! of! clinical! entities! cannot! be!assessed.!!This!chapter!describes!a!comparison!of! levels!of!miRJ122!release!between!groups! of! patients! with! several! different! liver! diseases.! This! will! allow! a!direct! comparison! of! the!miRJ122! release! in! different! types! of! injury.! The!levels! of! miRJ122! will! also! be! compared! to! traditional! markers! (AST)! to!assess! the! correlation! between! them.! Previous!work! has! shown! that!miRJ122! and! transaminases! are! well! correlated! following! acute! paracetamol!hepatotoxicity.!(171)!Finally!the!potential!role!for!miRJ122!in!the!diagnosis!of! hepatocellular! carcinoma! will! also! be! assessed! as! suggested! in! other!studies.!(173)!!
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3.2! Methods!!A! total! of! 194! patients!with! (n=104)! and!without!HCC! (n=90)! and!with! a!variety!of!chronic!liver!diseases!enrolled!along!with!healthy!controls!as!part!of!a!study!to!develop!a!novel!panel!of!biomarkers!for!primary!liver!cancer.!(Ethics!REC!reference!06/Q2707/182).!The!patients!were!stratified!into!10!groups!according! to!disease! type! (Table!11).!The!median!age!of! the!entire!cohort!was!61!(range!35J88).!Patients!were!recruited!from!the!Hepatology!clinic! and! cirrhosis! was! diagnosed! by! a! standard! combination! of! clinical!presentation,!imaging!and!biopsy.!!






3.3.1! Analysis!of!miR:122!levels!between!groups!!The! levels! of! miRJ122! were! assessed! between! the! different! groups.! The!group! of! patients!with! liver! disease! had! a! significantly! raised! serum!miRJ122!(p=<0.001)!than!the!normal!population!as!shown!in!Figure!36!!























































































































































































Receiver! operator! characteristic! (ROC)! curves!were! generated! to! compare!serum!miRJ122!and!serum!AST!for!use!in!the!diagnosis!of!inflammatory!or!cirrhosis!damage!to!the!liver.!!In! the! first! instance! the! sensitivity! of! miRJ122! to! detect! the! 2! types! of!damage! was! calculated.! MiRJ122! was! better! at! detecting! inflammatory!damage! with! an! Area! Under! the! Curve! (AUC)! of! 0.79! (p=<0.001)! than!cirrhosis!(AUC!0.54,!p=0.36)!as!shown!in!Figure!40.!!








hepatocyte!damage,!resulting!in!little!release!of!hepatocyteJspecific!markers!into! the! bloodstream.! A! second! possibility! is! that! by! the! time! established!cirrhosis! is! present,! liver! scarring! means! that! there! are! fewer! normal!functioning!hepatocytes!remaining!to!release!miRJ122! in!to!the!circulation!resulting! in!the! lowJnormal! levels.! It!may!be!that!serum!miRJ122!will!be!a!good!biomarker!for!certain!conditions!but!not!as!good!for!others.!!Serum! transaminases! have! been! shown! to! correlate! well! with!histopathological! liver! damage! (168)! and! previous! work! in! our! group! in!patients! with! acute! paracetamol! overdose! has! shown! good! correlation!between!serum!miRJ122!and!serum!ALT!(171).! In! this!study!there!was!no!correlation! between! serum!miRJ122! and!AST.! A! possible! explanation!may!be! that! most! other! studies! involve! lateJstage! damage! to! the! liver.! In! the!previous!studies!published!in!animal!models,!most!are!given!a!toxic!dose!of!drug! (169).! In! the! human! paper! published! by! our! own! group! (171)! the!patients!with!acute!paracetamol!overdoses!had!significant!hepatic!necrosis!requiring!admission!to!a! liver!transplant!unit.! It! is!known!that!serum!miRJ122!rises!are!detectable!before!the!serum!transaminases!rise.!Elfimova!et!al!suggested! that! before!miRJ122! and! transaminases! spill! out! of! a! disrupted!cell!membrane! into! the!bloodstream!that! there! is! release!of!miRJ122! from!intact!cells!via!another,!as!yet!undefined!mechanism.!(182)!This!position!is!strengthened! by! work! from! Bala! et! al,! who! have! shown! that! miRJ122! is!actively! released! from! cells! under! stress.! (183)! Given! that! our! population!represents! a! cohort! of! patients! living! at! home! and! attending! outpatient!clinic,!they!do!not!fall!into!the!endJstage!category.!It!is!possible!that!the!lack!of! correlation! between! serum! miRJ122! and! AST! is! as! a! result! of! active!release! of! miRJ122! from! a! viable! cell! prior! to! the! collapse! of! the! cell!membrane! leading! to! spilled! transaminases.! If! so! this! could! hint! at! a!potential,!important!role!for!miRJ122!in!the!early!diagnosis!of!liver!disease!and!injury.!!A!major!limitation!of!this!study!is!the!lack!of!more!clinicoJpathological!detail!on!each!of!the!patients.!Such!information!would!provided!more!insight!into!
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4.1! Introduction!!Patients! with! liver! metastases! from! primary! colorectal! cancer! are! often!considered! for! neoJadjuvant! chemotherapy! as! part! of! their! treatment.! In!those!with! irresectable! or! borderline! resectable! disease,! tumour! response!may!allow!resection!and!improve!survival.!(59;!61)!!It!also!identifies!those!in!whom!the!disease!is!progressive!and!in!whom!surgery!would!be!futile.!(51)!The!publication!of! the!MAGIC!trial! in!2006!showed!the!potential!benefit!of!neoJadjuvant! chemotherapy! in! resectable! gastrointestinal! cancer.! (50)! It!was!felt!that!this!approach!might!be!beneficial!in!colorectal!liver!metastases,!particularly!as!it!may!treat!microJmetastases!within!the!liver.!A!largeJscale!trial!was!set!up!to!investigate!this.!(56)!!ChemotherapyJinduced! hepatotoxicity! affected! up! to! 78%! of! patients!receiving! standard! chemotherapy! for! colorectal! cancer! and! can! lead! to!increased! morbidity! and! mortality.! (179)! Hepatotoxicity! presents! a!challenge!both!for!the!treating!oncologist!and!the!operating!surgeon!in!how!to!manage!the!impact!on!a!successful!outcome.!!Increasingly,!more! aggressive! chemotherapy! regimens! are! being! trialed! in!an! attempt! to! improve! survival! outcomes.! These! include! increasing! the!number! of! agents! used! in! combination! and! increasing! the! duration! of!chemotherapy.! Triple! therapy! with! 5JFU,! oxaliplatin! and! irinotecan!(FOLFOXIRI)!has!been!shown!to!significantly!increase!PFS!but!at!the!cost!of!increased! toxicity.! (184)! Similarly,! extended! treatment! (>9! cycles)! has!shown!no!survival!benefit!but!also!leads!to!increased!toxicity.!(185)!!There!remains!a!need!to!diagnose!significant!hepatotoxicity!preJoperatively.!It! remains! unclear! what! functional! impact! chemotherapyJinduced!hepatotoxicity!has!however!expert!opinion!is!that!more!future!remant!liver!should!be!left!to!allow!for!the!potential!of!impaired!function.!(104)!Thus!any!change! in! the! planned! operative! strategy! would! require! preJoperative!identification!of!hepatotoxicity.!Currently,!patients!receiving!chemotherapy!
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have! blood! sampling! at! each! cycle! measuring! the! liver! enzyme! ALT! as! a!marker! for!hepatic! damage.!Unfortunately,! patients! continue! to!present! at!laparotomy!with!chemotherapyJdamaged!liver!despite!having!normal!blood!tests! during! treatment.! A! new! biomarker! is! urgently! needed! to! allow!personalised!therapy!for!individual!patients.!!The!use!of!microRNAJ122!as!a!more! specific! and!sensitive!marker!of! liver!injury! is! currently! the! subject! of! much! research.! Following! on! from! the!previously! discussed! literature,! a! pilot! study! was! designed! to! assess! the!potential! role! of! this! novel! biomarker! in! the! preJoperative! diagnosis! of!chemotherapyJinduced!hepatotoxicity.!!
4.2! Methods!!
4.2.1! Patient!Recruitment!!Patients! were! recruited! under! the! National! Ethics! Research! Service!approved! study! “Biomarkers! for! hepatotoxicity! of! neoadjuvant!chemotherapy! for! colorectal! liver! metastases:! a! proof! of! principle! study!designed!to!evaluate! the!clinical!utility!and!value!of!novel!serum!markers”!(REC! ref.! 11/NW/0709).! Patients! due! to! receive! neoJadjuvant!chemotherapy! prior! to! surgical! resection! of! colorectal! cancer! liver!metastases! were! identified! through! the! Merseyside! and! Cheshire! SupraJregional!Specialist!MultiJdisciplinary!meeting!(sMDT)!at!University!Hospital!Aintree,!Liverpool.!Patients!who!had!received!previous!chemotherapy!were!excluded.! Suitable! patients! were! approached! and! given! a! RECJapproved!Patient! Information!Sheet!(PIS).!Those!who!were!willing!to!take!part!were!consented! and! entered! into! the! study! as! shown! in! the! Study! Protocol! in!Figure!42.!!
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!Figure!42:!Study!Protocol!for!Pilot!Study.!Patients!had!blood!samples!taken!routinely!prior!to!each!cycle!of!chemotherapy!and!liver!tissue!sampled!at!the!time!of!surgery.!!Patients!were! recruited! over! an! 18Jmonth! period! at! 3! centres:! University!Hospital! Aintree,! Royal! Liverpool! and!Broadgreen!University!Hospital! and!Clatterbridge! Cancer! Centre.! Having! been! identified! in! the! sMDT! at!University! Hospital! Aintree.! Patients! were! then! approached! in! the! Liver!Clinic!at!UHA!and!the!project!was!explained!to!them.!If!they!agreed!to!take!part,!consent!was!taken!prior!to!the!start!of!chemotherapy.!!Serial!blood!samples!were!obtained!as!part!of!their!standard!treatment!both!before! the! commencement! of! chemotherapy! and! before! each! treatment!cycle.! At! this! time! an! extra! 5ml! of! blood! was! taken! for! measurement! of!serum!miRJ122.!!


















centrifuged!at!1300g!for!10!mins!at!4!degree!Celsius!and!the!serum!stored!at!J80!degrees!Celsius!until!analysis.!!MiRJ122!levels!were!measured!by!qRTJPCR!as!described!in!Chapter!2.!The!results!were!expressed!as!both!Ct!value!and!number!of!copies/uL!of!serum.!!Histopathological!analysis!of! the!background! liver!parenchymal! tissue!was!conducted! by! a! Consultant!Histopathologist! at! University!Hospital! Aintree!from! the! resected! specimen.! Both! the! Consultant! and! myself! graded! it!according!to!the!Brunt!and!RubbiaJBrandt!scoring!systems.!!
4.2.3! Statistics!!Statistical! analysis! was! carried! out! using! GraphPad! Prism! (GraphPad!Software,!La!Jolla,!CA)!for!analysis!of!variance!(ANOVA)!and!using!SAS!(SAS!Institute! Inc,! Cary,! NC,! USA)! for! least! squared! means! analysis.! Statistical!significance!was!set!at!p=0.05.!!
4.3! Results!!Eleven! patients!were! recruited! in! the! 18Jmonth! period! between! February!2012!and!July!2013.!Of!these,!10!successfully!completed!their!neoJadjuvant!chemotherapy! and! proceeded! to! liver! resection! for! their! metastases.! One!patient! presenting! with! locally! advanced! synchronous! disease! failed! to!tolerate! the! chemotherapy! and! after! 4! cycles! it!was! be! abandoned! due! to!ongoing!sepsis!from!a!scrotal!abscess!and!poor!tolerance!of!the!prior!cycles.!Unfortunately,!disease!progression!in!both!sites!made!the!aim!of!treatment!purely!palliative.!!As! expected! the! majority! of! patients! were! those! with! advanced! (T3/4)!primary!tumours!and!multiple!liver!metastases.!The!majority!received!first!line! therapy! with! an! oxaliplatin! and! 5JFU/capcitabine! based! regime! in!keeping!with!NICE!guidelines.!Unfortunately!by!the!end!of!the!study!period,!
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60%!of!the!resected!patients!had!developed!recurrence!at!a!median!interval!of! 6! months! postJoperatively! and! 1! had! sadly! passed! away! from! their!disease.!The!full!demographics!of!the!patients!are!shown!below!in!Table!14!!Histopathological!analysis!of!the!resected!livers!showed!that!all!ten!resected!patients! had! some! form! of! potential! chemotherapyJrelated! injury! to! their!liver.!(Table!15)!Patients! ! N=!! Recruited! 11!! Underwent!Liver!Resection! 10!(91%)!! Age!(median)! 64!(47J80)!! Male! 8!(73%)!! Female! 3!(27%)!! ! !Presentation! Synchronous! 9!(82%)!! Metachronous! 2!(18%)!! ! !! Time!elapsed!to!metachronous!presentation! 16J33!months!! ! !Primary!Colorectal!Tumour!Stage! T1! 0!(0%)!! T2! 1!(10%)!! T3! 6!(60%)!! T4! 3!(30%)!! ! !! N0! 3!(30%)!! N1! 4!(40%)!! N2! 3!(30%)!! ! !! M0! 2!(20%)!! M1! 8!(80%)!! ! !Number!of!Metastases! Solitary! 3!(27%)!! Multiple! 8!(73%)!! ! !Chemotherapy!Regime! FOLFOX/OXMdG! 5!(45%)!! CAPOX! 5!(45%)!! FOLFIRI/IRIMdG!+!Cetuximab! 1!(10%)!3!! ! !Recurrence! Yes! 6!(60%)!! No! 4!(40%)!! ! !! Time!to!recurrence!(median)! 6!months!(1J13)!! ! !Mortality! ! 1!(9%)!at!20!months!postJop!Table!14:!Patient!demographics!from!“Biomarkers!for!Hepatotoxicity”!pilot!study!!!
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When!the!ALT!and!serum!miRJ122!results!were!compared!for!each!patient!it!appeared!that!they!followed!a!similar!pattern,!although!it!would!seem!that!the! miRJ122! levels! generally! rise! before! the! ALT! does.! Due! to! the! low!numbers!it!was!not!possible!to!perform!statistical!analysis!on!these!and!so!they!remain!descriptive!observations.!(Figure!49).!!
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4.4! Discussion!!ChemotherapyJinduced!hepatotoxicity!remains!a!significant!event!in!a!subJgroup! of! patients! receiving! chemotherapeutic! agents! for! advanced!colorectal! cancer.!The! ideal!biomarker!would!be!easy!and!safe! to!measure!and! be! able! to! detect! damage! at! a! point! before! any! clinically! significant!damage! was! done! allowing! therapy! to! be! altered! or! terminated! on! an!individual!patient!basis.!


































































































































Based! on! the! early! literature,!miRJ122! appears! to! be! a! good! candidate! to!fulfil! this!role.!This!pilot!study!was!carried!out! to!assess! the!potential! role!for!miRJ122!in!this!particular!clinical!situation.!!The!pilot!study!showed!no!significant!association!between!the!miRJ122!and!the! final! histology! of! the! resected! liver.! All! patients! had! some! form! of!histological!finding!(steatosis,!steatohepatitis!or!sinusoidal!obstruction)!that!is! found! in! association! with! chemotherapy! treatment! for! advanced!colorectal! cancer.! A! nonJsignificant! trend! to! increasing! levels! of! miRJ122!over! the! course!of! the! chemotherapy!was! seen!but! it! does!not!predict! the!degree! of! the! end! pathological! change.! A! statistically! significant,! but!clinically! insignificant,! rise! in! ALT! over! the! course! of! chemotherapy! was!seen.!Moreover,!in!7!of!the!11!patients!in!the!pilot,!the!level!of!miRJ122!was!at!some!point! in! the!treatment!over! the!range!previously!calculated!as! the!upper!limit!of!normal!in!a!normal,!healthy!population.!!Based!on!these!findings,!the!study!has!proved!the!Null!Hypothesis!and!has!shown! that! there! appears! to! be! no! role! for! miRJ122! in! the! diagnosis! of!chemotherapyJinduced! hepatotoxicity! in! the! treatment! of! advanced!colorectal!cancer.!!However,!the!low!recruitment!to!the!pilot!of!only!11!patients!of!which!only!10!had! liver!histology!available!raises!the!potential! for!a!Type!II!statistical!error! to! have! occurred.! It! is! possible! that! due! to! the! low!numbers! a! false!negative! result!has!occurred!and! the!Null!Hypothesis!has!been! incorrectly!accepted.!Despite!the!low!numbers,!there!are!a!few!interesting!findings!from!the!pilot.!!Despite! the! presence! of! liver! metastases,! other! medical! conditions! and!prescription! drugs! that! could! affect! the! liver,! the! baseline!miRJ122! for! all!patients!who!had! a! baseline! sample! available!was!within! the! limits! of! the!“normal! population”!we!had!defined! in! an! earlier! experiment.! (Figure! 44)!This!could!suggest!that!miRJ122!is!associated!more!with!acute!rather!than!
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chronic!disease!or!injury!processes!and!as!such!may!still!have!a!role!to!play!in!acute!chemoJ!or!drugJinduced!toxicity.!!MiRJ122! was! shown! to! correlate! well! with! ALT,! a! finding! that! has! been!shown!previously!in!humans!by!Starkey!Lewis!et!al!from!our!own!research!group.! (171)!The!graphs!of! the! individual!patients!results!seem!to!visually!confirm!this!as!the!profiles!of!the!graphs!are!very!similar.!What!is!noticeable!in!several!of!the!cases!is!that!the!miRJ122!seems!to!rise!a!cycle!or!so!before!the!ALT,!again!mirroring!previously!published!results!by!Starkey!Lewis!that!miRJ122!is!more!sensitive!than!ALT.!Elfimova!et!al!have!suggested!that!miRJ122! is! released! before! the! cell! membrane! is! damaged! by! other! as! yet!undescribed!processes.!(182)!!It! is! also! possible! that! the! end! histology! does! not! solely! report!chemotherapyJinduced! hepatotoxicity! in! these! patients.! Steatosis! is! very!common! in! the! general! population.! It! is! found! in! 10J24%! of! normal!individuals! and! in! up! to! 74%! in! obese! patients.! (186)! The! lack! of! a! preJchemotherapy! liver! biopsy!means! that!we! cannot! say! for! certain! that! the!steatosis!found!was!not!present!at!the!start!and!therefore!the!fact!that!there!was!no!rise!in!the!serum!miRJ122!reflects!that!there!was!no!new!damage!to!detect.! Steatohepatitis! and! sinusoidal! obstruction! are! less! common! and!more! directly! associated! with! chemotherapy.! Most! patients! showed! only!mild! or! no! sign! of! these! pathologies,! again! suggesting! a! potential!explanation! for! the!nonJsignificant! changes! in!miRJ122.!Although!not! seen!in!this!pilot!study,!a!potential! limitation!of!the!design!may!be!that!patients!who! develop! significant! hepatotoxicity! may! stop! therapy! early! and! not!proceed! to! surgical! resection.! This! could! lead! to! their! exclusion! from! the!pilot!and!the!potential!of!important!data!being!missed.!!
4.5! Conclusion!!The!results!of!the!pilot!study!do!not!confirm!a!role!at!present!for!the!use!of!miRJ122! as! a! biomarker! for! chemotherapyJinduced! hepatotoxicity! in! the!
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5.1! Introduction!!Hepatotoxicity! associated! with! chemotherapy! is! likely! to! increase! as! the!choice! and! availability! of! novel! drugs! becomes! greater.!With! increasingly!powerful! new! agents! and! different! combinations,! toxicity! and! sideJeffects!become!more! of! an! issue.! There! remains! a! need! for! better! biomarkers! in!general! for! the! detection! of! drugJinduced! liver! injury,! but! particularly! in!chemotherapy,!where!significant!sideJeffects!may!affect!the!intended!benefit!of!the!drug!in!terms!of!quality!of!life!and!outcome.!
(
5.2! MicroRNA:122!as!a!biomarker!for!hepatotoxicity!!The! need! for! more! sensitive! and! specific! biomarkers! of! hepatotoxicity!associated!with!cancer!chemotherapy!has!increased!over!the!last!ten!years!due! to! increased! choice! and! increased! use.! In! particular,! miRJ122! holds!considerable! promise! in! a! number! of! clinical! areas.! Recently,! there! have!been! a! number! of! key! papers! published! involving! human! patients! rather!than!animal!models.!Within!our!own!group,!Starkey!Lewis!et!al! showed! in!2011!that!miRJ122!was!released!earlier!than!ALT,!the!current!gold!standard,!and!that!it!was!more!sensitive!also.!(171)!Recently,!work!from!Rotterdam!by!van! der! Meer! et! al! has! also! shown! that! miRJ122! is! more! sensitive! in!detecting! hepatotoxicity,! in! their! case! in! patients! with! hepatitis! C! virus.!(188)!This!seems!to!confirm!the!potential!for!miRJ122!to!have!an!important!role!in!detecting!hepatotoxicity!in!the!future.!!Despite!ALT!being!the!current!gold!standard!biomarker!for!hepatotoxicity,!it!is! known! that! it! correlates! poorly!with! histopathological! damage.! (168)!A!new! biomarker! that! could! predict! the! extent! of! histopathological! damage!would! be! beneficial! in! clinical! practice.! Antoine! et! al! published! work! in!patients! who! had! taken! an! acute! paracetamol! overdose! resulting! in!admission!to!a!national!liver!transplant!unit.!They!showed!in!patients!with!initially! normal! standard! liver! function! tests! that!miRJ122! and! a! panel! of!other! novel! biomarkers,! could! strongly! predict! those! who! went! on! to!
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5.3! What! this! thesis! has! added! to! the! literature! on! miR:122! as! a!
biomarker.!!In!order!to!understand!abnormal,!one!must!understand!normal!first.!To!date!there! has! been! no! publication! in! the! literature! looking! to! understand! the!behaviour! of! serum! miRJ122! under! normal! conditions! in! either! animal!models!or!humans.!We!have!looked!at!the!serum!levels!of!miRJ122!in!terms!of! both! interJ! and! intraJpatient! variation! in! humans.!We! have! shown! that!serum!miRJ122! is!detectable! in!normal! levels!and! that! it! is! found!within!a!relatively! small! range! within! the! population.! There! is! neither! significant!circadian!variation!nor!longitudinal!change!over!several!days,!meaning!that!sampling!time!should!not!affect!the!validity!of!the!result.!!Throughout! the! literature! the!method! of! expressing! the! data! produced!by!the! PCR! process! varies! significantly! as! does! the! actual! methodology.! We!have!investigated!the!different!methods!of!normalising!and!expressing!data!and!shown!the!potential!strengths!and!weaknesses.!We!have!also!developed!a!novel!method!to!give!relative!quantification!that!can!be!adopted!whatever!methodology! is! used! allowing! for! valid! comparison! between! papers! and!results.!!It! is! important! that! more! baseline! work! is! carried! out! if! miRJ122! is! to!become!a!mainstream!biomarker.!Further!work!would!need!to!increase!the!numbers! and! expand! the! age! range! into! the! paediatric! and! elderly! age!ranges!to!firm!up!the!defined!normal!range.!!This! thesis! looked! at! healthy! individuals! with! no! past! medical! history! or!prescription! medications.!While! this! does! represent! a! “healthy”! cohort,! it!does!not!really!represent!a!population!“normal”!cohort.! In!such!a!“normal”!cohort! there!would!be!patients!with!a!variety!of!medical! conditions,! those!who! take! prescription! drugs! and! those!who! smoke! or! drink! alcohol.! This!would!be!a!much!more!clinically!relevant!control!population!and!it!may!be!valuable!to!expand!the!work!in!this!area.!!
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Although!there!are!a!significant!number!of!papers!published!looking!at!miRJ122!in!disease!and!injury,!these!nearly!all!focused!on!a!single!aetiology!and!the!differing!methods!and!data!expression!mean!that!comparison!between!them! is! not! possible.! We! have! compared! within! the! same! experiment! a!number!of!differing!aetiologies’!and!have!shown!that!there!is!a!difference!in!the! levels! of! miRJ122! released! into! the! circulation! depending! on! the!underlying!disease.!This!has!not!been!shown!in!the!literature!before!and!is!an! important! aspect! of! the! role! of! miRJ122! that! requires! further!investigation.!!The! patient! samples! available! for! this! experiment! were! historical,!retrospective!samples!for!which!detailed!clinicoJpathological!data!were!not!available.! It!would!be!preferable! to!design!a!prospective!experiment!along!these! lines,! sampling! patients! with! a! wide! variety! of! liver! diseases! and!injuries! but! also! collecting! good! quality! clinical! and! pathological! data! on!them!to!add!weight!to!the!subsequent!analysis.!!!
5.4! MicroRNA:122! as! a! biomarker! for! chemotherapy:induced!
hepatotoxicity!!The!evidence! for!a!role! for!miRJ122! in!drugJinduced!hepatotoxicity! is!well!documented! in! animal!models! and! has! been! confirmed! in! one! of! the! only!human!drug!toxicity!studies!performed!to!date!(171).!It!is!important!to!note!that! in! the! human! study,! clinically! significant! and! potentially! fatal!hepatotoxicity! was! seen! in! all! patients! following! acute! paracetamol!overdose.!This!represents!the!extreme!end!of!the!spectrum!of!DILI!whereas!the!pilot!study!described!in!this!thesis!was!designed!to!look!for!much!more!subtle! changes.! Whilst! many! of! the! patients! showed! histologically!observable! perturbation,! this! was! uniformly!mild,! and! is! unlikely! to! have!had! an! impact! on! either! the! ability! to! complete! the! chemotherapy! or! the!outcome.!!
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Learning!from!this!pilot!study,!there!are!a!number!of!changes!that!could!be!incorporated! into! a! larger! study! that! may! be! beneficial! in! improving! the!validity!of!the!results.!!The!first!is!the!number!of!patients!recruited.!Despite!only!being!a!pilot!study!and!therefore!not!being!powered,!it!is!clear!that!the!low!numbers!recruited!had!an! impact!on! the! results! and! findings.!By! increasing! the!numbers,! the!chances!of!a!false!negative!would!decrease.!The! second! is! the! timing! of! the! blood! sampling.! Patients! within! the! pilot!study!had!their!blood!samples!taken!prior!to!the!administration!of!the!next!cycle!of!chemotherapy.!Subsequent!work!from!Starkey!Lewis!(unpublished)!has!shown!that!the!halfJlife!of!miRJ122!is!short.!(Figure!50)!It!may!be!that!any! acute! rises! in! miRJ122! would! have! occurred! soon! after! the!administration!of!the!chemotherapy!and!that!by!the!time!the!blood!sample!was!taken!the!levels!had!returned!to!normal.!!
!Figure!50:!Unpublished!data!from!Dr!Philip!Starkey!Lewis!of!the!MRC!Centre!for!Drug!Safety!Science,!University!of!Liverpool.!This!shows!that!miRJ122!returns!to!normal!levels!quickly!compared!to!ALT!after!hepatotoxicity!caused!by!acute!paracetamol!overdose.!!Ideally! samples! should! be! collected! both! immediately! preJ! and! postJ!administration!of!the!chemotherapy!(up!to!24hrs!post)!rather!than!only!preJdelivery.! This! could! allow!acute! rises! in!miRJ122! to! be!detected! following!
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administration! of! the! drug.! This!would! involve! new! ethical! approval! as! it!would!mean!an!extra!blood! sample! that! is!not!part!of! standard! care! (post!chemo!sample)!and!this!may!also!impact!upon!compliance.!The! study! would! also! greatly! benefit! from! the! inclusion! of! a! preJchemotherapy! liver! biopsy! to! allow! direct! comparison! with! the! resected!postJchemotherapy!specimen.!This!would!allow!a!controlled!assessment!of!any!liver!damage!in!the!latter!biopsy,!and!the!assignment!of!chemotherapyJassociated! toxicity.! This! is! a!major! limitation! of! the! pilot! study! as! it! is! at!present.! The!delay!between! finishing! chemotherapy! and!having! surgery! is!also! a! confounding! variable! as! any! potential! liver! regeneration! cannot! be!taken! into! account.! It! is! of! course! unlikely! that! it! would! be! ethically!appropriate!to!perform!a!preJchemotherapy!liver!biopsy!as!the!risks!of!such!a! procedure! are! significant.! ! To! this! extent! the! development! of! animal!models! of! chemotherapyJinduced! hepatotoxicity! hold! great! promise! (192)!as!they!can!allow!the!preJ!and!postJchemotherapy!histology!that!would!be!extremely!valuable!information!in!assessing!the!role!of!miRJ122.!!
5.5! Chemotherapy!for!Colorectal!Liver!Metastases!!Recently!there!have!been!significant!developments!in!this!field.!Good!quality!evidence!is!particularly!hard!to!develop!in!clinical!medicine!as!technology!is!developing!so!quickly! that! longJterm!followJup!studies!are!old!before! they!complete.!The!landmark!study!when!I!started!this!thesis!was!the!EuropeanJwide! EPOC! trial! looking! at! the! role! of! neoJadjuvant! chemotherapy! in!colorectal!liver!metastases.!(56)!It!was!hoped!that!this!study!would!provide!the!evidence!for!the!role!of!neoJadjuvant!chemotherapy!that!many!experts!thought!was!logical!in!the!treatment!of!these!patients!and!indeed!early!data!suggested! a! longer! progression! free! survival! in! the! chemotherapy! group,!seemingly!vindicating!the!case!for!chemotherapy.!This! outcome!was! challenged! and! the! case! for! chemotherapy! revisited! in!2012,! when! at! the! annual! meeting! of! the! American! Society! for! Clinical!Oncology! (ASCO),! the! first! longterm! data! from! the! trial! was! presented!suggesting! no! overall! survival! benefit! occurred! from! the! use! of!
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chemotherapy! but! it! was! associated! with! more! sideJeffects.! The! data! has!since! been! published! confirming! the! lack! of! overall! survival! benefit.! At! a!median!followJup!of!8.5!years!the!hazard!ratio!was!0.88!(95%!CI!0.68J1.14,!p=0.34).!(187)!This!seemed!to!suggest!there!was!no!role!for!neoJadjuvant!chemotherapy!in!patients!with!resectable!disease.!The!authors!however,!state!that!given!that!PFS! was! the! primary! endpoint! and! that! OS! was! an! underJpowered!secondary! endpoint,! that! these! patients! should! still! receive! chemotherapy!based!on!the! increased!PFS!shown! in! the!original!paper.!At!present,!based!on! the! actions! of! the! sMDT! at! University! Hospital! Aintree,! the! use! of!chemotherapy! is! only! now! used! selectively! with! most! patients! with!resectable!disease!proceeding!directly!to!resection.!!The!potential!benefit!of!biological!agents!has!been!shown!in!studies!relating!to! irresectable! disease.! (69;! 71J73)! ! ! ! Given! the! excellent! response! rates!seen,!a!role!for!biological!agents!in!resectable!disease!was!hypothesised.!The!New!EPOC! trial,! sought! to! develop! the! evidence! for! cetuximab! in! patients!with! resectable! disease.! Patients! were! given! FOLFOX/FOLFIRI! +/J!cetuximab! in! a! randomised! phase! III! trial! that! closed! after! 100%!recruitment!of! it’s! intended!total.!Surprisingly!the!study!had!to!be!stopped!early! after! it! met! a! preJdefined! futility! analysis.! Early! analysis! showed!significantly! worse! PFS! in! the! cetuximab! arm! ((14.8! vs! 24.2! months,! HR!1.50037!(95%!CI!1.000707J2.249517),!p=<0.048).!Outcome!in!the!FOLFIRI!arm! was! also! worse! with! cetuximab! ((15.2! vs! 24.2months,! HR! 1.565546!(95%! CI! 1.014967J2.414793),! p=<0.043).! This! data! was! presented! at! the!ASCO!Annual!Meeting!in!2013!((J!Clin!Oncol!31,!2013!(sup;!abstract!3504)).!Full!publication!of!these!data!is!still!awaited,!but!the!data!presented!in!the!abstract! suggests! there! is!no! role! for! cetuximab! in!patients!who!are!KRAS!wild!type!and!have!resectable!liver!metastases.!!The!third!trial!under!the!EPOC!umbrella!was!the!EPOC!B!trial!attempting!to!answer!the!question!of!timing!of!chemotherapy.!This!was!a!pilot,!feasibility!study! randomizing! patients! to! preJ! or! postJoperative! chemotherapy.!
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Unfortunately,! the! trial! struggled! with! recruitment! and! was! closed!prematurely!with!only!25%!of!the!intended!numbers.!!These! three! trials! highlight! the!difficulties! faced! in! producing!high!quality!evidence!in!clinical!medicine.!Currently!the!use!of!chemotherapy!in!patients!with! colorectal! liver! metastases! remains! controversial.! There! is! general!agreement! that! it! is! indicated! in! the! initially! unresectable! or! borderline!patient,!and!the!evidence!for!this!is!well!founded!and!accepted.!(59;!61;!62)!!!The! debate! about! its! role! in! resectable! disease! continues.! Some!quote! the!futility! of! the! EPOC! family! of! trials! as! a! reason! not! to! give! chemotherapy,!while!the!advocates!of!chemotherapy!point!to!the!limitations!of!the!trial!as!a!reason!to!reject!the!findings.!A!systematic!review!carried!out!by!Primrose!et!al! in!2006! showed! that!up! to!61.3%!of!patients!who!had!a! liver! resection!developed!recurrent!disease!but!that!in!65%!of!them!the!recurrent!disease!was! extraJhepatic! in! nature.! This! adds! weight! to! the! argument! for!chemotherapy!by!showing!that!resectional!surgery,!which!is!organ!specific,!does! not! deal! with! the! systemic! nature! of! the! disease! for! which! the!chemotherapy!is!necessary.!!As!new!chemotherapeutics!are!developed!and!new!combinations!trialed,!the!role! for! chemotherapy! is! likely! to! increase.! Despite! the! often! negative!outcomes!of!trials,!advanced!colorectal!cancer!is!a!systemic!disease!and!can!only!be!treated!by!systemic!therapy.!!
5.6! Summary!and!review!of!hypotheses.!!The! first! rule! of!medicine! is! “do! no! harm”.! Chemotherapy! has! sideJeffects!and! it! is!being! increasingly! recognised! that! the! “one! size! fits! all”!dogma! is!not!the!way!forward!and!that!personalised!therapy!is!the!future.!In!patients!for! whom! it! is! felt! that! there! is! a! potential! benefit! of! chemotherapy,!undiagnosed! sideJeffects!may! have! an! overall! negative! outcome! for! them.!The! need! to! have! robust! biomarkers! of! toxicity! to! allow! alterations! in!therapy! on! an! individual! patient! basis! remains! a! key! focus! of! future!
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research.!To!this!end!we!set!out!to!explore!the!potential!role!of!microRNAJ122! in! the! early! detection! of! chemotherapyJinduced! hepatotoxicity! in!patients! receiving! neoJadjuvant! chemotherapy! for! the! treatment! of!advanced!colorectal!cancer.!!We!would!revisit!the!hypotheses!we!set!out!to!investigate;!!
• That!miRJ122!is!detectable!in!the!serum!of!healthy!human!subjects.!!





• MiRJ122! will! be! more! sensitive! than! serum! transaminases! in! liver!disease!and!injury.!!
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